Case 8:15-cv-03940-GJH Document 1 Filed 12/23/15 Page 1 of 66 CIVIL COVER SHEET

SJS 44 (Rev. 11/04)

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating

<u>`</u>	STRUCTIONS ON THE REVER	SE OF THE FORM.)			
I. (a) PLAINTIFFS			DEFENDANTS		
RoyaltyStat, LLC			IntangibleSpring	Corporation, et al.	
` '	of First Listed Plaintiff <u>M</u> XCEPT IN U.S. PLAINTIFF CAS	Iontgomery ES)	NOTE: IN LAN	of First Listed Defendant (IN U.S. PLAINTIFF CASES D CONDEMNATION CASES, U INVOLVED.	,
(c) Attorney's (Firm Name	Address and Talanhana Number		Afformers (If Known)		
DiMuroGinsberg PC, 110 703-684-4333	Address, and Telephone Number) 1 King Street, Suite 610		Attorneys (If Known)		
II. BASIS OF JURISD	ICTION (Place an "X" in 6	One Boy Only)	CITIZENSHIP OF P	RINCIPAL PARTIES	(Place an "X" in One Box for Plaintiff
		one not only)	(For Diversity Cases Only)		and One Box for Defendant)
☐ 1 U.S. Government Plaintiff	S Federal Question (U.S. Government N	lot a Party)		TF DEF I I Incorporated or P of Business In Th	
2 U.S. Government Defendant	Ø 4 Diversity (Indicate Citizenship)	o of Parties in Item III)	Citizen of Another State	1 2	
			Citizen or Subject of a Foreign Country	3 Foreign Nation	□ 6 □ 6
IV. NATURE OF SUIT	(Place an "X" in One Box Only TOR		FORFEITURE/PENALTY	BANKRUPTCY	OTHER STATUTES
□ 110 Insurance □ 120 Marine □ 130 Miller Act □ 140 Negotiable Instrument □ 150 Recovery of Overpayment ∞ Enforcement of Judgment □ 151 Medicare Act □ 152 Recovery of Defaulted Student Loans (Excl. Veterans) □ 153 Recovery of Overpayment of Veteran's Benefits □ 160 Stockholders' Suits □ 190 Other Contract □ 195 Contract Product Liability □ 196 Franchise REAL PROPERTY □ 210 Land Condemnation □ 220 Forcelosure □ 230 Rent Lease & Ejectment □ 240 Torts to Land □ 245 Tort Product Liability □ 290 All Other Real Property	□ 315 Airplane Product Liability □ 320 Assault, Libel & Slander □ 330 Federal Employers' Liability □ 340 Marine □ 345 Marine Product Liability □ 350 Motor Vehicle □ 355 Motor Vehicle □ 360 Other Personal Injury CIVIL RIGHTS □ 441 Voting □ 442 Employment □ 443 Housing/ Accommodations □ 444 Welfare □ 445 Amer. w/Disabilities - Employment	PERSONAL INJURY 362 Personal Injury - Med. Malpractice 365 Personal Injury - Product Liability 368 Asbestos Personal Injury Product Liability PERSONAL PROPERTY 370 Other Fraud 371 Truth in Lending 380 Other Personal Property Damage Product Liability PRISONER PETITIONS 510 Motions to Vacate Sentence Habeas Corpus: 530 General 535 Death Penalty 540 Mandamus & Other 550 Civil Rights 555 Prison Condition	□ 610 Agriculture □ 620 Other Food & Drug □ 625 Drug Related Scizure of Property 21 USC 881 □ 630 Liquor Laws 640 R.R. & Truck □ 650 Airline Regs. □ 660 Occupational Safety/Health □ 690 Other LABOR □ 710 Fair Labor Standards Act □ 720 Labor/Mgmt. Relations □ 730 Labor/Mgmt. Reporting & Disclosure Act □ 740 Railway Labor Act □ 790 Other Labor Litigation □ 791 Empl. Ret. Inc. Security Act	□ 422 Appeal 28 USC 158 □ 423 Withdrawal 28 USC 157 PROPERTY RIGHTS ■ 820 Copyrights □ 830 Patent □ 840 Trademark SOCIAL SECURITY □ 861 HIA (1395ff) □ 862 Black Lung (923) □ 863 DIWC/DIWW (405(g)) □ 864 SSID Title XVI □ 865 RSI (405(g)) □ FEDERAL TAX SUITS □ 870 Taxes (U.S. Plaintiff or Defendant) □ 871 IRS—Third Party 26 USC 7609	400 State Reapportionment 410 Antitrust 430 Banks and Banking 450 Commerce 460 Deportation 470 Racketeer Influenced and Corrupt Organizations 480 Consumer Credit 490 Cable/Sat TV 810 Selective Service 850 Securities/Commodities/Exchange 875 Customer Challenge 12 USC 3410 890 Other Statutory Actions 891 Agricultural Acts 892 Economic Stabilization Act 893 Environmental Matters 894 Energy Allocation Act 895 Freedom of Information Act 900 Appeal of Fee Determination Under Equal Access to Justice 950 Constitutionality of State Statutes
⊠1 Original □ 2 R	tate Court /	Remanded from Appellate Court	Reinstated or 3 anoth Reopened (speci		
VI. CAUSE OF ACTION			iling (Do not cite jurisdiction		es, and injunctive relief
VII. REQUESTED IN COMPLAINT:		IS A CLASS ACTION	DEMAND \$		if demanded in complaint:
VIII. RELATED CASS	(See instructions):	JUDGE		DOCKET NUMBER	
12/23/2015		signature of attol /s/ Billy B. F	general	57774	R
FOR OFFICE USE ONLY RECEIPT #	AMOUNT	APPLYING IFP	JUDGE	MAG. JU	

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MARYLAND

Greenbelt Division

RoyaltyStat LLC,	*	
5335 Wisconsin Ave., N.W.	*	
Suite 920	*	
Washington, D.C. 20015-2084	*	
	*	
Plaintiff	*	
	*	
v.	*	
	*	
IntangibleSpring, Corp.	*	
Torre ADR, Piso 6	*	
Avenue Samuel Lewis y Calle 58	*	Case No.:
Panama City, Panama 0816-04373	*	
•	*	•
Serve: John Di Giacomo	*	
Revision Legal	*	
109 E Front Street	*	
Suite 309	*	
Traverse City, Michigan	*	
49684-2532	*	
	*	
and	*	
	*	
Raul Pacheco Quintanilla	*	
(As if "John Doe" and not to be Served at this	*	
time)	*	
Defendants.	*	

COMPLAINT

1. Over 20 years, Ednaldo Silva ("Dr. Silva") drew upon his expertise in economics, statistical analysis, transfer pricing and intangible valuation to develop a unique way to aggregate information relating to licensing of intangible assets and transfer pricing to make such information accessible to clients. Dr. Silva's business, RoyaltyStat LLC ("RoyaltyStat") has become the leading purveyor of this information to governments, businesses, and legal professionals alike. The significance of RoyaltyStat's curated data and statistical tools has been

widely recognized around the world because Dr. Silva has invested in quality control and promoting the RoyaltyStat brand.

- 2. RoyaltyStat has invested several million dollars in developing and promoting its database, and continues to invest over a million dollars each year to maintain the high quality product and customer service that RoyaltyStat's clients and potential clients have come to expect.
- 3. In the spring of 2013, however, RoyaltyStat's primary competitor noticed a new-comer to the intangible license/tax field and brought it to Dr. Silva's attention. Most significantly, this new business, IntangibleSpring, Corp. ("IntangibleSpring") boasted it possessed the same client list as RoyaltyStat, and began asserting it provided the same data provided by RoyaltyStat at a significantly lower cost.
- 4. Alerted to this information, RoyaltyStat began investigating IntangibleSpring and learned that it was started by one of RoyaltyStat's own former independent contractors, Raul Pacheco Quintanilla ("Mr. Pacheco"). Further investigation revealed that Mr. Pacheco, immediately prior to being terminated by RoyaltyStat, accessed its data files and stole RoyaltyStat's proprietary data, which he used to form a competitor business under the name IntangibleSpring.
- 5. IntangibleSpring's misappropriation of RoyaltyStat's trade secrets and proprietary data significantly eroded RoyaltyStat's profits. Moreover, its false advertising claims have lured clients from RoyaltyStat, thereby causing irreparable harm. By relying upon and incorporating RoyaltyStat's data, IntangibleSpring violated federal and state laws. This action seeks redress for these injuries.

JURISDICTION AND VENUE

- 6. This Court has jurisdiction over this case pursuant to 28 U.S.C. §§ 1331, 1332(a)(2) and 1338.
 - 7. Venue is proper in this Court pursuant to 28 U.S.C. § 1391(b)(2).

PARTIES

- 8. RoyaltyStat LLC is a limited liability company formed under the laws of the State of Maryland with its principal place of business at 5335 Wisconsin Avenue, N.W., Suite 920, Washington, D.C. 20015-2084, on the border of Maryland and Washington D.C.
- 9. IntangibleSpring, Corp. is a corporation organized under the laws of Panama with its principal place of business in Panama City, Panama. Defendant Raul Pacheco Quintanilla is a principal in IntangibleSpring. The company provides a database of royalty rates ostensibly based upon unredacted license agreements filed with the United States Securities & Exchange Commission ("SEC"). IntangibleSpring claims to provide a website featuring non-downloadable software for analyzing and evaluating the value of intangible property such as royalties and license fees. IntangibleSpring apparently hosts its website, www.intangiblespring.com, through a domain host located in Houston, Texas.
- 10. Upon information and belief, Raul Pacheco Quintanilla is a citizen of Brazil and Mexico. He resides at various times throughout the year in either France, Belo Horizonte, Brazil, or Mexico City, Mexico. Upon information and belief, Mr. Pacheco runs IntangibleSpring, and makes claims to such effect in the business network LinkedIn. Because Mr. Pacheco takes affirmative steps to avoid disclosing his precise location, RoyaltyStat is unable to effect service of process and names him herein as if he was a "John Doe" defendant. Once his precise location can be ascertained, RoyaltyStat intends to effect service of process and join Mr. Pacheco herein.

FACTUAL ALLEGATIONS COMMON TO ALL COUNTS

RoyaltyStat LLC Offers Unrivaled Access to License Agreement Data and Analysis

- 11. Since launching its online presence on February 2, 2000, RoyaltyStat has provided to paid subscribers a reliable source of royalty rates extracted from unredacted license agreements. An unredacted license agreement contains disclosed royalty rate information, and other monetary licensing consideration, such as upfront and milestone payments. A large percentage of material license agreements filed with the SEC are redacted to remove critical information such as the royalty rate, upfront fees, minimum license fees, and other forms of monetary compensation. This information can be very valuable to government tax administrations and to corporate taxpayers complying with the arm's length standard of IRC section 482, and complying with similar standards under the OECD (Organization for Economic Cooperation and Development). RoyaltyStat has expended and continues to expend a great deal of effort and money to identify and obtain unredacted agreements, and to extract searchable data fields from them. The information RoyaltyStat makes available to paid subscribers is used in transfer pricing, purchase price allocation, intellectual property valuation, and for due diligence connected with litigation, corporate bankruptcy, business development, and mergers and acquisitions.
- 12. RoyaltyStat's online database of license agreements represents a significant investment in time and money over the course of its 20 year business history. Many of the license agreements in the collection can only be obtained through exhaustive public record searches or by submission of Freedom of Information Act ("FOIA") requests.
- 13. Full access (*e.g.*, the capability to search for comparables, read records, select comparable records to the taxpayer's intangible property, and download data) is tightly

controlled within RoyaltyStat. Only a limited number of authorized employees and contractors have been given such access. Mr. Pacheco was among those given such access while he was supposed to be working exclusively for RoyaltyStat.

- 14. All of RoyaltyStat's employees and contractors have been required to sign confidentiality/non-disclosure agreements as a condition of receiving access to the database. Sometime in 2009 RoyaltyStat asked its employees and contractors to re-execute these agreements.
- 15. RoyaltyStat has a client base of more than 200 subscribers ranging from corporations to government agencies to professional services firms (*e.g.*, law firms and international accounting firms). RoyaltyStat's client list is also closely guarded. RoyaltyStat has never made its customer list public and restricts access to the information to certain employees and contractors of the company on a need-to-know basis.
- 16. RoyaltyStat's subscribers, who pay an annual subscription fee, can search its unique proprietary online database containing more than 16,500 unredacted license agreements to identify comparable royalty rates by selecting filters, including Standard Industrial Classification ("SIC") codes, intangible property type (copyright, patent, trademark), and keywords. In addition, subscribers get access to financial information and annual reports for more than 34,000 publicly traded companies.
- 17. In order to keep its database current, RoyaltyStat is one of the most prolific filers of FOIA requests. Because so much of the data in its database can only be compiled from information that is only available through this laborious and expensive process, a significant time commitment and investment were and are necessary to build and maintain the database to its current level.

- 18. Before receiving access to the RoyaltyStat database, subscribers must execute a Subscription Agreement.
- 19. The Subscription Agreement expressly prohibits subscribers from "modify[ing], decompil[ing], disassembl[ing], or reverse engineer[ing] RoyaltyStat, the License Agreements

 Database, its process, its content, or any portion thereof." RoyaltyStat Subscription Agreement, ¶

 5.6.
- 20. Further the Subscription Agreement expressly prohibits subscribers from "assembl[ing] or us[ing] the License Agreements Database, or any data or documents obtained from the License Agreements Database, in any manner that violates RoyaltyStat's copyrights or that competes with, substitutes for, or is an alternative to RoyaltyStat's subscription services." *Id.*, ¶ 5.7.
- 21. In addition, by signing the Subscription Agreement, subscribers acknowledged and agreed that "RoyaltyStat, the License Agreements Database, its process, its content, and any portion thereof constitute and contain valuable proprietary information and trade secrets of RoyaltyStat and/or its suppliers, embodying substantial creative efforts and confidential information, ideas, and expressions. Accordingly, Subscriber[s] agree[s] to treat (and take precautions to ensure that [their] employees treat) RoyaltyStat, the License Agreements Database, its process, its content, and any portion thereof as confidential and to exercise at all times a reasonable degree of care in the protection of confidential information." *Id.*, ¶ 8.
- 22. Each of these controls was put in place to protect RoyaltyStat's copyrights and trade secrets.

Raul Pacheco Quintanilla's Relationship to RoyaltyStat LLC

- 23. From 1982 until 1990, Ednaldo Silva served as a very successful and well-regarded professor of economics on the Graduate Faculty of the New School for Social Research in New York City. While teaching, he became a dissertation advisor to Claudio Gontijo. As a result of this relationship, Dr. Silva developed a long standing personal relationship with Dr. Gontijo's stepson, Mr. Pacheco.
- 24. In 2000, Dr. Silva offered Mr. Pacheco an internship working with RoyaltyStat. Subsequently, working as an outside contractor, Mr. Pacheco began as a reader extracting data fields from license agreements that RoyaltyStat purchased. Ultimately, Mr. Pacheco began working in customer service and sales. In both capacities, he was given unlimited access to the RoyaltyStat License Agreements Database, its process, its content, and its trade secrets. As a result of the unfettered access he was given to this confidential and proprietary information, Mr. Pacheco owed a fiduciary duty of loyalty to RoyaltyStat.
- 25. Mr. Pacheco's primary responsibility at RoyaltyStat was to sell new subscriptions and to provide customer service to subscribers. For each subscription he sold, Mr. Pacheco was obligated to obtain an executed Subscription Agreement and he was required to ensure such subscribers understood the limitations of use embodied in the Subscription Agreement as set forth *supra*.
- 26. For each such subscription sold, Mr. Pacheco received a commission. His right to payment continued for periodic customer service functions he performed related to renewals of all subscriptions, including those he had sold.

- 27. In late 2009, RoyaltyStat learned that Mr. Pacheco was embezzling funds from the company by having certain Latin American subscription fees routed to his personal account in Mexico, instead of going to RoyaltyStat's account in the U.S.
- 28. On September 23, 2011, RoyaltyStat terminated its relationship with Mr. Pacheco for cause, including abandonment of customer support work, deception, and failure to sell new subscriptions.

Raul Pacheco and IntangibleSpring Misappropriated RoyaltyStat's Trade Secrets

- 29. Even before his termination, Mr. Pacheco began sowing the seeds of his efforts to undermine RoyaltyStat. On December 1, 2010, Mr. Pacheco accessed and downloaded/exported RoyaltyStat's database data into an Excel spreadsheet. On two other occasions, December 14, 2010 and January 28, 2011, he stole additional data from RoyaltyStat.
- 30. On three additional dates, Mr. Pacheco accessed RoyaltyStat's back-office library and downloaded unredacted license agreements collected by RoyaltyStat not for use in connection with performing his duties to RoyaltyStat, but to use for his own personal gain.
- 31. All of these items that Mr. Pacheco downloaded were protected trade secrets.

 They were only accessible for download using access afforded to a strictly limited and tightly controlled number of persons associated with RoyaltyStat, and were only allowed to be downloaded to perform assigned quality control tasks on behalf and for the sole benefit of RoyaltyStat. The information Mr. Pacheco purloined could not be downloaded from RoyaltyStat's database or servers using a client access login. It required back-office access using an additional administrative login.

- 32. Having stolen RoyaltyStat's proprietary and confidential trade secrets, Mr. Pacheco set out to establish a company that would compete directly against RoyaltyStat. On August 8, 2012, IntangibleSpring Corp. was formed in Panama.
- 33. RoyaltyStat first learned of IntangibleSpring's existence in April 2013 when a competitor, contacted Dr. Silva to alert him. At that time the competitor advised RoyaltyStat that, to the competitor's surprise, IntangibleSpring had RoyaltyStat's customer list and had almost precisely the same number of records in its database as RoyaltyStat had as of the time Mr. Pacheco was fired. Not coincidentally, the number of records cited by the competitor was almost identical to the number of records stolen by Mr. Pacheco on the dates, identified above.
- 34. RoyaltyStat's customer list was not publicly available at that time, or any time before or thereafter.
- 35. By April 19, 2013, IntangibleSpring claimed that its database contained more than 10,500 records. IntangibleSpring falsely claimed to be adding more than 600 records per month.
- 36. Upon information and belief, IntangibleSpring and Mr. Pacheco have falsely claimed to offer the same data and analysis that is the same or substantially the same in quality and content as that provided by RoyaltyStat.
- 37. The only analysis IntangibleSpring offers comparable to that provided by RoyaltyStat has been stolen from RoyaltyStat.
- 38. For example, some of IntangibleSpring's database records contain content copied verbatim from RoyaltyStat. As reflected in Exhibits A and B, a comparison of database data from the two companies reveals identical sentence structure and punctuation in both databases. Such similarity can only occur by rote copying from one source to another because the text at

issue was drafted by RoyaltyStat personnel analyzing source agreements. The cited text does not appear in the original source agreements filed with the SEC.

- 39. Further, some of these records in IntangbileSpring's database containing content copied verbatim from RoyaltyStat correspond to records added to RoyaltyStat's database after September 2013. IntangibleSpring could only have obtained the copied material in conjunction with someone possessing access to RoyaltyStat's database. Such person necessarily must be either RoyaltyStat personnel or a RoyaltyStat customer. In either case, the individual IntangibleSpring obtained the information from could only provide the information in violation of a confidentiality agreement.
- 40. Mr. Pacheco has contacted several of RoyaltyStat's customers and offered subscriptions of stolen data for about 1/3 of the RoyaltyStat regular subscription price. Several former RoyaltyStat customers who switched to IntangibleSpring, who are reputable businesses have confirmed that they would not have switched except for the deception and significantly lower prices offered by Mr. Pacheco.
- 41. By misrepresenting the product it offers as being comparable in content, but lower in price to that provided by RoyaltyStat, IntangibleSpring has enticed some of RoyaltyStat's customers to switch to its service. This has caused RoyaltyStat to lose significant revenue and profits.

COUNT I:

VIOLATION OF THE COPYRIGHT ACT, 17 U.S.C. § 101 ET SEQ.

- 42. RoyaltyStat incorporates paragraphs 1-40 as if fully set forth herein.
- 43. RoyaltyStat is the owner of all rights, title and interest in and to the copyrights in its database. RoyaltyStat's database is the subject of U.S. Copyright Registration

TX0007233781, dated May 7, 2009 (the "'781 Registration"). A copy of the '781 Registration as obtained from the U.S. Copyright Office's online records is attached as Exhibit C. The RoyaltyStat database is also the subject of U.S. Copyright Application entitled "RoyaltyStat Royalty Tableau," which was filed with the U.S. Copyright Office on December 21, 2015 (the "Royalty Tableau Application"). A copy of the Royalty Tableau Application as filed is enclosed as Exhibit D.

- 44. RoyaltyStat's copyrights protect the original expression in (a) the selection, coordination and arrangement involved in choosing material and data for inclusion in the database; classifying, categorizing, ordering, or grouping the material and data; and determining the placement and arrangement of material and data within the database as a whole; and (b) RoyaltyStat's original authorship, such as original textual content, that appears within the database.
- 45. Defendant Raul Pacheco Quintanilla had access to and copied RoyaltyStat's original authorship which was then used by Mr. Pacheco and Defendant IntangibleSpring to create the IntangibleSpring database. The IntangibleSpring database contains text, material and data that is substantially similar, if not identical, to that of RoyaltyStat's original authorship in its database.
- 46. Defendants have thus reproduced, prepared a derivative work based on, and/or distributed RoyaltyStat's copyrighted work, including the original expression identified above and covered by the '781 Registration and Royalty Tableau Application. Defendants' actions have been without RoyaltyStat's permission or authority, and violate RoyaltyStat's exclusive rights in its original work of authorship. Defendants' actions therefore constitute copyright infringement pursuant to the Copyright Act, 17 U.S.C. § 501.

- 47. RoyaltyStat has been damaged by Defendants' infringement, including suffering harm for which there is no adequate remedy at law.
- 48. RoyaltyStat is entitled to an award of either statutory or actual damages suffered by it as a result of Defendants' infringement, and any profits of Defendants that are attributable to the infringement. RoyaltyStat is also entitled to entry of an injunction against further violations of RoyaltyStat's copyrights by Defendants.

COUNT II:

FALSE ADVERTISING IN VIOLATION OF THE LANHAM ACT, 15 USC § 1125(a).

- 49. RoyaltyStat incorporates paragraphs 1-48 as if fully set forth herein.
- 50. Upon information and belief, Defendants' have represented to their clients and potential clients, including those who are current or former clients of RoyaltyStat, that IntangibleSpring's database is the same as RoyaltyStat's in content and quality, but is offered for a lower price. RoyaltyStat devotes substantial resources to updating its database and assuring that the data is of the highest integrity. As a result of these substantial efforts over many years, RoyaltyStat and its founder, Dr. Silva, have developed a reputation for the high-quality of the RoyaltyStat database. Apart from portions of RoyaltyStat's database that they have copied, Defendants have not and cannot maintain a database of similar quality. Defendants' cannot therefore offer a database product that is similar to RoyaltyStat's in content and quality for a lower price.
- 51. Defendants' statements constitute a false and misleading representation of fact regarding the nature and quality of both the RoyaltyStat database and the IntangibleSpring database. Defendants' actions were undertaken to deliberately trade on the goodwill and reputation RoyaltyStat has developed as a result of the high quality of its product and services.

Defendants' actions therefore constitute unfair competition and false advertising pursuant to § 43(a) of the Lanham Act, 15 U.S.C § 1125(a).

- 52. Defendants' actions have been undertaken willfully and with a deliberate intent to deceive.
- 53. RoyaltyStat has suffered damages as a result of Defendants' actions, including harm for which there is no adequate remedy at law.
- 54. RoyaltyStat is therefore entitled to recover Defendants' profits, damages sustained by it, increased up to three times, costs of this action, and RoyaltyStat's attorney fees.

 RoyaltyStat is also entitled to entry of an injunction against further violations by Defendants.

COUNT III:

VIOLATION OF THE MARYLAND UNIFORM TRADE SECRETS ACT

- 55. RoyaltyStat incorporates paragraphs 1-54 as if fully set forth herein.
- 56. RoyaltyStat's customer list, its License Agreements Database, its process, and its content each constitutes and contains valuable proprietary information and trade secrets of RoyaltyStat.
- 57. At all times relevant hereto, RoyaltyStat took reasonable measures designed to protect the confidentiality of its trade secrets. Among the measures employed, RoyaltyStat controlled access and disclosure through, *inter alia*:
 - a. Controlling access to its database through assigned login/password combinations;
 - Limiting the scope of access to persons based upon the level of access required for their respective purpose;
 - Requiring employees and contractors to execute confidentiality and/or nondisclosure agreements;

- d. Requiring customers to execute Subscription Agreements containing confidentiality and non-disclosure provisions;
- e. Controlling and limiting access to its customer list.
- 58. RoyaltyStat derives independent economic value from its trade secrets inasmuch as subscribers pay for the service for the sole purpose of receiving access to the substantial creative efforts and confidential information, ideas and expressions appearing in its License Agreements Database.
- 59. Raul Pacheco Quintanilla and IntangibleSpring misappropriated RoyaltyStat's trade secrets by using the information Mr. Pacheco downloaded from RoyaltyStat's database and publishing the same as if it was IntantigibleSpring's own work product in direct competition with RoyaltyStat.
- 60. Raul Pacheco Quintanilla's and IntangibleSpring's wrongful actions proximately caused RoyaltyStat to suffer injury in the form of, *inter alia*, lost subscription revenue and profits.

COUNT IV:

TORTIOUS INTERFERENCE WITH CONTRACT

- 61. RoyaltyStat incorporates paragraphs 1-60 as if fully set forth herein.
- 62. RoyaltyStat had existing contracts with customers obligating them to protect the confidentiality of RoyaltyStat's proprietary information and trade secrets as defined in the Subscription Agreement.
- 63. RoyaltyStat's employees and contractors all executed, and are bound by, non-disclosure and non-competition agreements that obligate the employees to protect the confidentiality of RoyaltyStat's proprietary information and trade secrets.

- 64. Raul Pacheco Quintanilla and IntangibleSpring knew or should have known of the obligations imposed on RoyaltyStat's customers by virtue of the Subscription Agreement.
- 65. Raul Pacheco Quintanilla and IntangibleSpring knew or should have known of the obligations imposed on RoyaltyStat's employees and contractors by virtue of the non-disclosure and non-competition agreements such persons executed in the course of their employment.
- 66. Raul Pacheco Quintanilla and IntangibleSpring tortiously interfered with RoyaltyStat's contracts by inducing one or more of RoyaltyStat's subscribers or employees, after Mr. Pacheco was no longer associated with RoyaltyStat, to provide him with copies of RoyaltyStat database content.
- 67. The defendants' actions are the direct and proximate cause of significant injury to RoyaltyStat in an amount to be proved at trial.

REQUEST FOR PERMANENT INJUNCTION

- 68. RoyaltyStat incorporates paragraphs 1-67 as if fully set forth herein.
- 69. As detailed above, the defendants' wrongful actions are causing, and will continue to cause irreparable injury to RoyaltyStat in the form of loss of goodwill and reputation, loss of business opportunities, and price erosion, in a manner for which there is no adequate remedy at law.
- 70. RoyaltyStat therefore seeks, and is entitled to, an order enjoining the defendants from using, publishing, or selling any of RoyaltyStat's data, proprietary information, or trade secrets on the internet or in any other form.
- 71. RoyaltyStat will suffer irreparable harm if the relief sought herein is not granted.
- 72. Because of the unique nature of the injuries caused by the defendants' wrongful actions, RoyaltyStat has no adequate remedy at law.

WHEREFORE, the Plaintiff, RoyaltyStat, LLC, requests:

- A. That this Court award compensatory damages jointly and severally against the defendants in an amount equal to the value of RoyaltyStat's actual damages and/or defendants' profits resulting from the violation of RoyaltyStat's intellectual property rights;
- B. That this Court award statutory damages jointly and severally against the defendants and pursuant to 17 U.S.C. § 504(c)(1) in an amount not less than \$30,000.00 for each violation of the United States Copyright Laws;
- C. That this Court award punitive damages jointly and severally against the defendants in an amount up to three times the amount of the damage award to RoyaltyStat;
- D. That this Court enter an Order temporarily and permanently enjoining the defendants from using, publishing, or selling any of the data, proprietary information, or trade secrets misappropriated from RoyaltyStat;
- E. That this Court award Plaintiff their costs of suit and their reasonable attorney's fees incurred pursuing this action; and
- F. Such other and further relief as this Court deems necessary and appropriate.

Case 8:15-cv-03940-GJH Document 1 Filed 12/23/15 Page 18 of 66

Dated: December 23, 2015

Respectfully Submitted,

/s/ Billy B. Ruhling, II
Billy B. Ruhling, II, Fed. Bar No. 17827
DIMUROGINSBERG PC
1101 King Street
Suite 610

Alexandria, VA 22314
Telephone: (703) 684-4333
Facsimile: (703) 548-3181
bruhling@dimuro.com
Counsel for Plaintiff RoyaltyStat LLC

Text from Intangible Spring Database	RoyaltyStat Database Text	Company
Products related rotavirus vaccines for humans.	Exclusive patent and technical	AVANT
	information license to make,	IMMUNOTHERAPEUTICS
	have made, use, lease, sell,	
	have sold and sublicense	
	products and processes related	
	to rotavirus vaccines for	
	humans.	
Injectable vaccine containing the nonionic	Option to a co-exclusive patent, technology and know-how	VAXCEL INC
surface-antigen influenza virus vaccine, to	license to develop,	
enhance the immune response in humans	manufacture, use, distribute and	
through Phase I human clinical trials.	sell an injectable vaccine	
	conclymer known as "CRI -	
	1005" combined with fluvirina, a	
	purified-surface-antigen	
	influenza virus vaccine, to	
	enhance the immune response	
	in humans through Phase I	
	numan chincal mais.	
Pharmaceutical formulations related to a	Exclusive patent and know-how	VAXGEN INCGenentech,
recombinant Human Immunodeficiency Virus	license to develop, make, have	Inc. / VaxGen, Inc.
(HIV) surface glycoprotein gp 120 Vaccine, for the	made, use, sell, and sublicense	
prevendon, but not treatment, or my infection and/or AIDS in humans.	pharmaceutical formulations	
	related to a recombinant	
	Human Immunodeficiency Virus	
	(HIV) surface glycoprotein gp	
	120 vaccine, for the prevention,	
	but not treatment, of HIV	
	infection and/or AIDS in	
	humans, with option for	
	licensor to market and sell	
	products.	



eadinforce tribbing on the beauties of a subtraction between the DM feet of a subtraction of the subtraction of

anitsense molecules, pharmaceutical products, cantagonists, vaccines and modulators. h	Exclusive paterit and technology	INFEMINION PHILA HILC.
	cross-license with rovalty-free	
	know-how license to make,	
0 11	have made, use, import, market,	
	offer, and sell the "GDF-8" TGF-	
	B Factor formulations,	
wi	antibodies, receptors, anitsense	
드	molecules, pharmaceutical	
<u>ы</u>	products, antagonists, vaccines	
	and modulators	
Biopharmaceutical products, including	Purchase of rights related with	BIOVEST
monoclonal antibodies, peptides, infectious	patented biopharmaceutical	INTERNATIONAL INC
ancer	products, including monoclonal	Valens Offshore SPV II
vaccines such as for non-Hodgkins lymphoma	antibodies, peptides, infectious	Corp. / Biovest
cell-based therapies,	disease and cancer vaccines,	International, Inc.
roduced by	autologous cancer vaccines	
mammalian cell culture techniques.	such as for non-Hodgkins	
	lymphoma and renal cell	
01	carcinoma, cell-based	
	therapies, stem cells, cytokines,	
(O)	and viruses produced by	
	mammalian cell culture	
Ţ.	techniques.	
Pharmaceutical products consisting of DNA		Vascular Biogenics Ltd
sing	Nonexclusive patent, know-how	
licensee's vascular targeting system platform in	and process license to develop,	
	use, import, manufacture, have	
	made, offer and sell	
tic	pharmaceutical products	
	consisting of DNA sequences	
	obtained from the Per.C6 cells	
1	using licensee's vascular	
	targeting system platform in	
5	combination with the genome of	
	a serotype 5 human adenovirus,	
	to treat cancer in humans using	
101	an adenoviral vector, including	
	therapeutic gene sequences,	
	but not serving as a vaccine.	

œ
_
ത
Ω
\subseteq
⊂
0
7
$\mathbf{\mathcal{C}}$
_
≍
.≌
ription
Ω
_
$\overline{\Omega}$
m
ă۲
~
\Box
- 1
ı.
5
=
Ċ
≒
_
\simeq
느
0
ပ
·=
⊢
7.
ıΨ
S
മ
=
Ω
≔
-5
\times

Text from IntangibleSpring Database	RoyaltyStat Database Text	Company
Integrated circuits which include the Jazz PSA Platform, a logical hardware design for a general purpose, programmable multiprocessor macroarchitecture, Jazz VLIW microprocessors, computation units, and integration blocks, including the host bus interface, directed memory access controller, and external memory controllers.	Nonexclusive patent, technology and trademark license to design, have designed, manufacture, distribute and sell integrated circuits known as "iNSECT PSA ICs," which include the Jazz PSA Platform, a logical hardware design for a general purpose, programmable multiprocessor macro-architecture, Jazz VLIW microprocessors, computation units, and integration blocks, including the host bus interface, directed memory access controller, and external memory controllers.	QUICKLOGIC
Integrated circuits employing high performance CMOS processes on a silicon substrate having only an array of programmable logic cells consisting of basic gate and flip-flop elements interconnected by row and columns of programmable wiring channels.	Nonexclusive patent, copyrights and technology license to make, use, sell, lease and dispose of integrated circuits employing high performance CMOS processes on a silicon substrate having only an array of programmable logic cells consisting of basic gate and flip-flop elements interconnected by row and columns of programmable wiring channels.	QUICKLOGIC
Integrated circuits, chips, or chipsets using the mixed signal processor having a power output stage capable of amplifying only audio signals to a total output power of 25 watts or less per channel, when measured at 10% total harmonic distortion into a 4-ohm resistive load.	Nonexclusive patent and copyright license to make, have made, use, sell, offer and import integrated circuits, chips, or chipsets using the Mixed Signal Processor "MSP" core having a power output stage capable of amplifying only audio signals to a total output power of 25 watts or less per channel, when measured at 10% total harmonic distortion into a 4-ohm resistive load, and having significant additional functionality.	TRIPATH TECHNOLOGY INC
Membrane and filter manufacture and design for integrated circuits, semiconductors, semiconductors, semiconductor chips, microelectronics components, flat panel displays, solar cells, fiber optic cables, optical coatings, and coated optical fibers.	Option to exclusive patent license to make, have made, use, and sell products related to membrane manufacture. filter manufacture, and filter design, to companies that manufacture integrated circuits, semiconductors, semiconductors, semiconductor chips, microelectronics components, flat panel displays, solar cells, fiber optic cables, optical coatings, and coated optical fibers, as well as to integrated circuit IC and OEM equipment manufacturers, integrated circuit research laboratories, and to companies that manufacture, process and supply liquids, gases, and conductive materials.	MILLIPORE CORP /MA

EXHIBIT

Sign

Copyright Office of the United States

WASHINGTON, D.C.

THIS IS TO CERTIFY that on May 7, 2009 a claim to copyright a work identified as ROYALTYSTAT WEBSITE ROYALTY TABLEAU was registered under TX 7-233-781. This work was registered in accordance with provisions of the United States Copyright Law (Title 17 United States Code).

THIS IS TO CERTIFY FURTHER, that the attached is an additional certificate of this work.

<u>IN WITNESS WHEREOF</u> the seal of this Office is affixed hereto on November 20, 2015.

Maria A. Pallante Register of Copyrights

By: Jarletta Walls

Supervisory Copyright Specialist Records Research and Certification Section Office of Public Records and Repositories

Use of this material is governed by the U.S. copyright law 17 U.S.C. 101 et seq.

EXHIBIT

Signature

C

C

Miditional Certificate (1/៦ CY-03940-GJH Document 1 Filed 12/23/15 Page 23 of 66

Certificate of Registration

Certification



This Certificate issued under the seal of the Copyright Office in accordance with title 17, United States Code, attests that registration has been made for the work identified below. The information on this certificate has been made a part of the Copyright Office records.

Register of Copyrights, United States of America

Registration Number TX 7-233-781

Effective date of registration:
May 7, 2009

Title Title of Work: Royaltystar website royalty tableau Completion/Publication Year of Completion: Nation of 1st Publication: United States Date of 1st Publication: May 7, 2009 Author Author: Royaltystat LLC Author Created: text Work made for hire: Yes Domiciled in: United States Citizen of: United States Copyright claimant Copyright Claimant: Royaltystat, LLC 5404 Blackistone Road, Bethesda, MD, 20816-1821, United States Rights and Permissions Royaltystat, LLC Organization Name: -Ednaldo A. Silva Name: Email: esilva@royaltystat.com 5404 Blackistone Road Address: Bethesda, MD 20816-1821. United States

Name: Marcus G. Theodore, agent

Date: May 7, 2009

Case 8:15-cv-03940-GJH Document 1 Filed 12/23/15 Page 24 of 66

Registration #: TX0007233781

Service Request #: 1-190968612

Royaltystat; LLC-Ednaldo A. Silva 5404 Blackistone Road Bethesda, MD 20816-1821 United States

Copyright Office of the United States

WASHINGTON, D.C.

THIS IS TO CERTIFY that the attached color photocopies are a true representation of the work entitled ROYALTYSTAT WEBSITE ROYALTY TABLEAU deposited in the Copyright Office with claim of copyright registered under number TX 7-233-781

THIS IS TO CERTIFY FURTHER, that due to the nature of the work deposited, the attached color photocopies are the best possible electrostatic positive prints available.

<u>IN WITNESS WHEREOF</u>, the seal of this Office is affixed hereto on November 20, 2015.

Maria A. Pallante

Register of Copyrights

By: Jarletta Walls

Supervisory Copyright Specialist Records Research and Certification Section Office of Public Records and Repositories

Use of this material is governed by the U.S. law 17 U.S.C. 101 et seq.

STOY DY STATE

Folders Search Edit Login Logoff

Saved Searches Create Invoice Library Contact

You have 818 agreements remaining on your limit of 1000 agreement(s).

RoyaltyStat® On-Line 2834 - Patent Archive contains 9 agreement(s).

O New Folder	Delete From Archive		Licensed Intangible		sell fast dissolving oral strips and oral gel,		Assignment of all rights, title, and interest in trademarks "Humibid," used in connection with pharmaceutical expectorant products.	9
	(6)			. 08/05/2007 08/14/2008 1.50 %	Net Sales Yes	Exclusive	02/15/2005 05/13/2005 2.00 % Net Sales Yes	
图 — OD 事	2834 – Patent (9)	05		Effective Date: SEC Fled Date: Royalty Rate:	Royaity Base: Tigred Royalty:	icals, Inc. čaciosive:	Effective Dater. SEC Plea Date: Royalty Rater. Royalty Baser	ma, Inc. Inc.
Statistics			nent Details	15516 2834 Gamma Pharmaceuticals Inc	10-() POF Trademark Jugular, Inc.	Gamma Pharmaceuticals, Inc. 14 year(s) Exclusiv Worldwide	16627 2834 Adams Respiratory Therapeutics, Inc. 5-1/A PDF Trademark	Cornerstone Biopharma, Inc. Adams Laboratories, Inc.
Sta	MOVE DOCS TO CODY DOCS TO GO TO	Sort Archive By: RoyaltyRate	Document/Agreement Details	Reference. SIC Code: SEC Pheri	SEC Fläng: Agreement Type: Licersor:	Licensee Duration Other Payments: Ternton,	Reference: SIC Code. SEC Filen: SEC Filen:	Ucansor: Licanses:
	Move D	Sort A		î +		Advisor	- C	ST PA

Case 8:15-cv-03940-GJH Document 1 Filed 12/23/15 Page 27 of 66

			-	
	Exclusive license to use the "BioFIT" trademark to use, market, manufacture, sell and distribute herbal dietary supplements in tablet, 2-piece hard-shell and gelatin capsures delivery forms, including St. Johns Worf, Echinacea, Saw Palmetto, Ginseng and Ginkgo Biloba initially.	Exclusive trademark license to promote, seil and sublicense prescription or over-the-counter pharmaceutical specialties containing Modafinil.	Amendment to exclusive trademark license.	Nonexclusive license to use the trademarks in connection with the
	Effective Date: 10/30/1998 8335 SEC Filed Date: 05/18/1999 9aracelsian Inc /De/ Royalty Rate: 3.00 % 10x\$2/A POF Royalty Base: Net Sales Trademark Tierac Royalty: Yes Paracelsian, Inc. R.P. Scherer North America 1.5 year(s) Exclusive: Exclusive Milestone payments are \$50,000 for each of the 1st 5 customers to accept the initial products. Art. 6.1. New product upon acceptance by 2 customers. Art. 6.2. Canada; Mexico; United States	01/1993 08/16/1999 4.00 % Net Sales Yes Exclusive	07/21/1993 08/16/1999 4.00 % Net Sales Yes Exclusive	12/01/2000 11/14/2000
	Effective Date: SEC Filed Date: Royalty Rate: Royalty Base: Tiered Royalty: Tiered Royalty: Terica Exclusive: Exclusive: are \$50,000 for each the initial products. are \$50,000 for each the Alta for each owners. Art. 6.2.	Effective Date: SEC Filed Date: Royalty Rase: Royalty Base; Thered Royalty: Exclusivat	Effective Date: SEC Fled Date: Royalty Base Tiered Royalty: Exclusive:	Effective Date: SEC Fired Date:
Unknown	9655 Effective Date: 10/30/1998 2835 SEC Filed Date: 05/18/1999 Paracelsian Inc /De/ Royaity, Rate: 3.00 % 10XSB/A POF Royaity Base: Net Sales Trademark Tierec Royaity: Yes Paracelsian, Inc. R.P. Scherer North America 1.5 year(s) Exclusive: Exclusive: Milestone payments are \$50,000 for each of the 1st 5 customers to accept the initial products. Art. 6.1. New product upon acceptance by 2 customers. Art. 6.2. Canada; Mexico; United States	255 2834 Cephalon Inc 10-Q PDF Trademark Genelco Cephalon, Inc. 99 year(s) Mexico; United States	15596 2834 Cephalon Inc 102; PDF Trademark Genelco SA Cephalon, Inc. 20 year(s) Europe	1949 2834
Other Payments: Terntony:	Reference: SEC Code: SEC Filer SEC Filing Agreement Type: Ulcensee: Duration: Other Payments:	Reference: SIC Code: SEC Filen: SEC Filen: SEC Filen: Agreement Type: Licenses: Licenses: Durabon: Other Payments: Techtory:	Reference SIC Code: SEC Piling. Agreement Type: ucensor. Licenses: Duration: Obser Payments:	Reference: SSC Cade.
	(o (in the second	4	C C T	()

Case 8:15-cv-03940-GJH Document 1 Filed 12/23/15 Page 28 of 66

manufacture, marketing, advertisement, promotion and distribution of dermal management products under the trademarks. Carrington, Carrasyn, CarraGauze, CarraSorb, CarraGinate, CarraFilm, SurgiSuites, CarraKlenz, CarraClenz, CarraClenz, CarraClenz, CarraFoam, CarraWash, CarraFree, CarraScent, CarraWash, CarraPere, CarraScent, CarraFresh, CarraPere, Diab, and RadiaCare.	Exclusive patent, technology and know-how license to use the "Donovex" trademark to import, store, distribute, use and sell products containing the pharmaceutical compound Calcipotriane, a vitamin D anaiogue with the formula CZ7H4003 for human therapeutic use in the field of dermatology, with right to sublicense.	Exclusive patent license to promote, distribute, market, advertise, sell or offer the extended release ciprofloxacin HCI pharmaceutical product under the "Proquin XR" trademark.	Amendment to settlement regarding the "Levall" brand of cough and cold medication, including Levall 12, Levall—G and otner products.
5.00 % Net Sales Yes Non-Exclusive In Islands	09/01/2005 01/05/2004 10.00 % Net Sales Yes Exclusive	07/21/2005 11/09/2005 25.00 % Net Sales Yes Exclusive	01/01/2007 02/26/2007 50.00 % Net Sales Yes
Royalty Rater Royalty Base Traceo Royalty: ies, Inc. nc. Exclusive: United States; Virg	effactive Date: SEC Flod Date; Royalty Base: Tored Royalty: d.	Effective Date: SEC Filed Date: Royalty Base: Tered Royalty: Exclusive:	Effective Date: SEC Fled Date: Royalty Rate: Royalty Base. Tlered Royalty:
Carrington Royalty Rate 5.00 % Laboratories Inc. /Tx/ 10-0 PDF Royalty Base Net Sal Trademark Tiereo Royalty: Yes Carrington Laboratories, Inc. Mediline Industries, Inc. 5 year(s) Exclusive: Non-Exc Canada; Puerto Rico; United States; Virgin Islands	4660 2834 Galen Holdings Plc 20-F/A PbF Trademark Leo Pharma A/S Galen (Chemicals) Ltd 20 year(s) United States	8053 2834 Depomed Inc 10-Q PDF Patent Trademark Depomed Inc Esprit Pharma Inc 20 year(s)	1071.1 2834. Auriga Laboratories, Inc. E-K. PDP. Asset Porchase Trademark
SEC Filer: SEC Filling: Agreement Type: Licensor: Licenser Duration: Other Payments: Territory:	Reference: SIC Code: SEC Filer: SEC Filer: SEC Filer: Agreement Type: Licenson: Ucersee: Duration: Other Payments: Territory.	Aefarence SIC Code: SEC Filing: SEC Filing: Agreement Type: Licensor: Licensor: Licensoe: Chration: Other Payments:	Reference: Siz Code: Siz Filen: Siz Files: Agreemanr Type:
9		∂ ∞ ∰	() O 🚛

New Folder

Unknown

Exclusive:

Unknown

Other Payments:

Unknown

Ternitory:

Athlon Pharmaceuticals, Inc. Auriga Laboratories, Inc.

> Licensee! Очгадоп:

LICENSON:

Ø

(S)

2834 - Patent (9)

Move Docs To | Copy Docs To | Go To

Statistics Statistics





















Intellectual Property | Intangible Assets | Royalty Rates Subscribe | Royalty Rate Search | Library | Valuation Contact Us Home Copyright © RoyaltyStat LLC 04/17/2009 Website by woodbourne solutions



Receipt

Copyright Office Library of Congress 101 Independence Avenue SE Washington DC 20559-6000



No. 1-1D86911


Date: 12/21/2015 13:08:54

Received					Services
Form(s): Deposit Count: Piece to Count: Type of Deposit: Other Enclosures: Title: # Additional Titles: Priority: # of Documents:	TX (1) 1 1 text RoyaltyStat Royalty	Tableau		Other:	Search Report Search Retrieval Correspondence Inspection Photocopies Additional Certificate Certification Secure Test Exam
Received From:	RayaltyStat LLC 5335 Wisconsin Avenue Suite 920 Washington DC 20015	» NW	Pho	one: () -	
Representing:			Pho	ne: () -	
Correspondence ld:				(4,
Fees		Method of Pa	yment	Amount	
No Fee; Fee to be Determined Base Fee; Special Handling Fee Secure Test Exam Fe	\$85.00 e: \$ ee: \$	Method of Pa Check: Money Order: Deposit Accou Deposit Accou	.nt:	Amount	
No Fee; Fee to be Determined Base Fee; Special Handling Fee	\$85,00 : \$	Check: Money Order: Deposit Accou	.nt:	Amount \$85.00	Visa
No Fee; Fee to be Determined Base Fee; Special Handling Fee Secure Test Exam Fe	\$85.00 e: \$ ee: \$	Check: Money Order: Deposit Accou Deposit Accou Credit Card	int: int Name:	\$ 85.00	ord fridates communications of the

Receipt of material is merely a preliminary step in the registration and/or recordation process. It does not imply that any final determination has been made in the case, or that the material is acceptable for registration.

Official action on an application for copyright registration or a document for recordation can be taken only after there has been a full examination of the claim following regular Copyright Office procedures. We are glad to discuss questions involving copyright registration on the telephone or in person-to-person conversations. However, all statements made during these exploratory discussions must be considered provisional, and are not binding either upon the applicant or upon the Office.

This receipt acknowledges delivery of the material to the Copyright Office on the date indicated. When multiple claims are submitted by or on behalf of the same remitter, however, only one receipt will be provided. If you are submitting multiple claims, only one title will appear on the receipt.



0	Form TX For a Nondramatic Literary Work UNITED STATES COPYRIGHT OFFICE
	UNITED STATES COPYRIGHT OFFICE

REGISTRATION NUMBER

Privacy Act Notice: Sections 408-410 of title 17 of the *United States Code* authorize the Copyright Office to collect the personally identifying to Ş

Augustic whice has no estigated a flerage. Ter curani iesa, wresk far Calvillat Ciffic which the ed rember on prolifying good within the Weight

ngor Sare, er celi (20s) for ener-

	uested on this form in order to proc it registration. By providing this info		TX TXU					
reeing to rout give legal not 05. It will appe e information	the uses of the information that include of your copyright claim as required in the Office's online catalog. If your requested, registration may be refu	ude publication red by 17 U.S.C. I do not provide sed or delayed,	EFFECTIVE DAT	E OF REGISTRAT	ION			
id you may no ider the copyr	it be entitled to certain relief, remedi- ight law.	as, and benefits	Month	Day	Year			
NOT WRIT	E ABOVE THIS LINE. IF YOU NE	ED MORE SPACE, USE A SEPARATE CONTINUATION	N SHEET.					
e interette fotogr 					POTARRAS ASSESSES AS TOUR LOS			
	RoyaltyStat Royalty Table	au						
				·				
	PREVIOUS OR ALTERNATIVE	TITLES						
	PUBLICATION AS A CONTRII collective work in which the contribution	BUTION If this work was published as a contribution to a per lion appeared. Title of Collective Work ▼	iodical, serial, or colle	ection, give inform	ation about the			
	If published in a periodical or serial g		Issue Date ♥		ageš ▼			
lilla iste versinger. Verhal 2004 i	NAME OF AUTHOR ▼	e egistett (f. fram af endant til stat stort i morestenste er et månde fyrid fyridings sæligstigte er egis et e	DATES OF BIR	TH AND DEAT	Н			
	RoyaltyStat, LLC		Year Born ▼	Year Died				
The state	Was this contribution to the work a "work made for hire"?	AUTHOR'S NATIONALITY OR DOMICILE Name of Country	WAS THIS AU THE WORK	THOR'S CONT	RIBUTION TO			
	Yes	OR Citizen of United States	_ Anonymous?	Yes No	of these questions is "Yes," see detailed			
	□ No	Domiclled In			instructions.			
IOTE	NATURE OF AUTHORSHIP Briefly describe nature of material created by this author in which copyright is claimed. ▼ Selection, coordination and arrangement in material and data; original text, material and data.							
der the law, "author" of	NAME OF AUTHOR ▼		DATES OF BIR	TH AND DEAT				
work made hire is a solution of the solution o			Year Born ♥	Year Died				
ployer, not employee	Was this contribution to the work a	AUTHOR'S NATIONALITY OR DOMICILE Name of Country	WAS THIS AU THE WORK	THOR'S CONT				
e instruo- ns), For any	"work made for hire"?	Citizen of	_ Anonymous?	☐ Yes ☐ No	If the answer to either of these questions is "Yes," see detailed			
rt of this rk that was	Ů №	OR Domiciled in	Pseudonymous?	☐ Yes ☐ No	Instructions.			
ade (or hire" ock "Yes" in space	NATURE OF AUTHORSHIP Briefly, describe nature of material created by this author in which copyright is claimed. ▼							
vided, give employer other	NAME OF AUTHOR ▼		DATES OF BIR Year Born ▼	TH AND DEAT Year Died				
om the work is prepared)	Was this contribution to the work a	AUTHOR'S NATIONALITY OR DOMICILE	WAS THIS AU	THOR'S CONT	RIBUTION TO			
"Author"of it part, and	"work made for hire"? \[\sum \text{Yes} \]	Name of Country. Citizen of	THE WORK Anonymous?	☐ Yes ☐ No	If the answer to either of these questions is			
ve the ace for dates	□ No	OR Domiciled in	Pseudonymous?		"Yes," see detailed instructions.			
birth and ath blank,	NATURE OF AUTHORSHIP B	riefly describe nature of material created by this author in which						
illes de la 1845 est. Ser e								
	YEAR IN WHICH CREATION OF WORK WAS COMPLETED TH	is information Complete this information Month INOVE	HIGHTON OF T	Year Year	ARWORK			
. H	2015 Year In	ist be given A ONLY if this work all cases. has been published.	Barigario Auglideo Perer de	timisto isa kija dikunga kifatan kij	Nation			
	COPYRIGHT CLAIMANT(S) N the author given in space 2. ▼	ame and address must be given even if the claimant is the same	ne as APPLICATION RECEIVED					
		sconsin Ave., N.W., Suite 920, Washington,	H 는 ONE DEPO	SIT RECEIVED				
e instructions	D.C. 20015-2084		ONE DEPO					
ore completing space.	TRANSFER IEtha daimantlel name	d here in space 4 is (are) different from the author(s) named in	TWO DEPC	SITS RECEIVED				
		the claimant(s) obtained ownership of the copyright.	FUNDS RE	CEIVED				
			<u> </u>		-			
			1					

MORE ON BACK ► Complete all applicable spaces (numbers 5-9) on the reverse side of this page.

• See detailed instructions.
• Sign the form at line 8:

DO NOT WRITE HERE.

	Case 8:15-cv-03940-GJH Document 1	Filed 12/23/15 Page 32 of 66	71.0507	antotararolikas jõuga			
		EXAMINED BY		FORM TX			
	4	CHECKED BY					
		CORRESPONDENCE		FOR COPYRIGHT			
		└── Yes	z zi	OFFICE USE ONLY			
			terrore de la constitución de la c				
DREXMOTIC	DO NOT WRITE ABOVE THIS LINE. IF YOU NEED MORE SPACE, US REGISTRATION Has registration for this work, or for an earlier version of this w	om destina et placest de destina de colonia de la competita de la competita de la competita de la competita de	TTT TO	y was e ose o sinoon e			
	o If your answer is "Yes," why is another registration being sought? (Check appropr	49 War and 1					
	ne first published edition of a work previously registered in unpublished form, ne first application submitted by this author as copyright claimant.			No. in			
. 🗖 This is a	changed version of the work, as shown by space 6 on this application.						
lf your answei	r is "Yes," give: Previous Registration Number ▶ TX0007233781	Year of Registration ► 2009	and the same and	itare conterto cura e			
	/E WORK OR COMPILATION laterial Identify any preexisting work or works that this work is based on or incorpo	valence 😿	.074);	jina			
rieexisting in	tatettat metitiy aty preexisting work of works that this work is based on or incorpo	Acca. Y	271				
ath S. J. S. S. Star place of a star transport and his country beautiful to the star of the star of the star of				See Instructions			
Material Add	ed to This Work Give a brief, general statement of the material that has been added	o this work and in which copyright is claimed. ▼		pelore completing his space.			
Registran work.	nt continued to add material and data of the same nature as	that included in the previously registered	13				
DEPOSIT A Name V	ACCOUNT If the registration fee is to be charged to a deposit account established in Account Number		inere Vali	er Harri Habita († 1906) Gregoria			
	ONDENCE Give name and address to which correspondence about this application			₹ <u>₹</u>			
Cecil E. I	Key, DiMuroGinsberg P.C., 1101 King Street, Suite 610, Ale	exandria, Virginia, 22314	lt.				
Area code and c	däyfime telephione number ▶ (703) 684-4333	Fax number ► (703) 548-3181					
	ey@dimuro.com nace and proposition to the rest spin spin spin spin spin spin spin spin			and the property of			
	TION* I, the undersigned, hereby certify that I am the		1-11-457-11-11	ina milini (M.) - 1.5, M.; 1987 - 1			
	Check only one ▶ ☐ other copyrigi	rsive cight(s)					
of the work id by me in this	lentified in this application and that the statements made.	ent of RoyaltyStat, LLC me of author or other copyright claimant, or owner of exclusive right(s)		1.1.50 mm / mm			
	ited name and date ▼ If this application gives a date of publication in space 3, do not		_				
Cecil E. I		December 21, 2015					
	Handwritten signature ♥	Date >	_				
	(hie Kruz						
5 (2000 BETALL) (125)							
Certificate	Name ▼ Camplete all necessary spaces Sign your application in space 8.						
will be mailed in window	Number/Street/Apt ▼	1. Application form					
envelope to this address:	City/State/Zip ▼	Nonrefundable filing fee in check order payable to Ragister of Copyrig 3. Deposit material MAIL TO: Library of Congress Copyright Office-TX	nts	<i>;</i>			
autorista atauskas.		101 Independence Avenue SE Washington, DC 20559	TO VENEZO O	Control of the Contro			

17 U.S.C. \$506(e). Any person who knowingly makes a false representation of a material fact in the application for copyright registration provided for by section 409, or in any written statement filled in connection with the application, shall be fined not more than \$2,500.

Case 8:15-cv-03940-GJH Document 1 Filed 12/23/15 Page 33 of 66



FO 502 (TOAPAGE) I HANGA (FESAGRIAGE

DASHBOARE

SEARCH 1 69

MY ACCOUNT

FEATURES V

Folder: Copyrights (50) - RoyaltyTableauTM •

чоуп	ity Tabic	nau Net Sales % (50	All Agreements > Filter Costs	or const		Folder		Expor	t to	Ţ
			O transitati tratinen uden a situa sirana elleri etterata a vinaspueleri era para ar ar silanda olo.					Was news of a feet again.	trop with white	116 7
9 -	P\$(#)	ologia (m. 1800). 1907 - Maria Maria, 1907 (m. 1804). 1908 - Maria Maria, 1907 (m. 1804).	TRANSLATE	ROVAL	TY WATE					
elle T	ariac	Aegls Therao≘u⊭os, LLC /	Exclusive option for exclusive paters, know-how, process and		5.DQ %	lvet Sales	Eti'tis	Know-hely, Option.	Worldwide	
Fe .	Gelects	Lightleke Therapeutics, Inc.	trademark license to research, develop, make, have made, use, sell,		.0.007 78	rient ciaina		Palani, Process,	AvioLiganios	
'a	CAR')		ofter, impent, expert, commercialize, expect and sublicense pharmaceutical formulations containing nationane using the 'Intraval's delivery agents (Area					Hesaarch, Supply, Technology, Trademark		
	91126	The Penn State Research	Exclusive patent and know-how license to make, have made, use,	17	10.50 %	Net Sales		Know-how, Fatent,	Worldwide	
eg.	Selection.	Foundation / Innovive	lease, sell, practice, have practiced and sublicense products and					Process		
٠.	a.E.	Phamaceuticals, inc.	processes retailed to opioid growth factor, taxanes, and gemetabline to treat cancer, for all human uses in the field of oncology and to treat						1.5	
			heap.u. Afgye	4.0	'		'			٠
i. L	31122	SensorMedics Corp. a/lda	Monexclusive patent ticense to develop, make, have made, use, have		5.00 %	Net Sales	•	Patent	Miles de la companya	. '
,		CareFusion / Advanced Inhalation	used, self, offer, have sold and intoon products, services and delivery		.0.00 NA	usi Osida		Latein	Worldwide	
Ä.	Selection of the select	Theraples (AIT) Lta.	devices using okide and in tric oxide therapy to treat diseases or conditions in hurrians, excluding veterinary applications.							
		and the second s	para PARA an ilay katamba		ona itt	non in Sociedado			1237 (812)	
	3193 6	ARYx Therapeuros, Inc. / Procier & Gamble Pharmacout pals, Inc.	Explusive patent, know-how, arricess and technology idense to exploit, make, have made, import, use, set, offer, dispose of;		6.00 %	Net Sales		Process,	Wordwide	
4	Selecti		research, develop, manufacture, formulate, export, commercialize,			5.3		Technology		
	Karalia.		promote, distribute and sublicense non-presonation OTC products containing a serior. Mark	4						
	Ħ			·			·		1.1.	5,
	21:30%	ARYX Therapoulas, Ico. / Progler	Exclusive patent, know-how, process and technology licence to	* *	20.00 %	Net Sales		Know-how, Paterit	Japan,	
Ž.	Sulgett	& Gamble Pharmaceut curs, Inc.	exploit, make, have made, import, use, self, offer, dispose of,			1 5-02-2		Process,	Worldwide w	vith:
5 .	(is)		research, develop, manutacture, formulate, export, commercialize, promote, distribute and sublicense prescription products containing a					echnology	Exceptions	
	Ħ		serotonia typ, Métre						·	
	11931	Renovis, Inc. / Pfizer Inc.	Exclusive patent, know-now and technology license to menutacture,		12.00%	het Sales		Know-how, Fatent,	Worldwide	•
	delect.		use; sail, offer, import and sublicense VR-1 antagonists, either as a single agent or in combination, to treat human diseases or discrears,	·				Technology	1,01-0,110-2	·
::	Cas.		including neuropathic pain, chronic pain, headache, bladder, colon							
			an (杜) (1) (1) (1) (1) (1) (1) (1) (1) (1) (1			:	1			4.
; ;	31985	ChemoGentryx, Inc. / Claxo Group	On laborative research, with exclusive option for exclusive patent;	* . * *	19.00 %	Kat Sales	- :-	Know-how, Cation.	Worldwide w	ر
· ·	Volca:	Lid.	know-how and technology license to make, have made, use, se',		12190 (2	1101 0,044.		Patent, Hesearch.	Exceptions	reșe s
<i>5</i>	4.1		offer, import and sublicense therapout to products containing small. molecule drug candidate compounds that tagest chemotine					Technology		
H	() C)		receptors, to freat o Store							
	E									
I.	91077	ARVx Therapeupos, Inc. / Procter	Exclusive patent know-how, process and technology idease to	19 7 1	25.00 %	Nat Sales		Know-how, Patent,	United State	s.
٠	Sules:	& Camble Pharmaceut oa's, Inc.	exploit, make, have made, import, use, sell, offer, dispose of,	٠.				Process,	in it is a single	
9	138		research, develop, manufecture, formulate, export, commercialize, promote, distribute and sublicense prescription products containing a					Technology		1
			sarotonin typ tidana		, P. J.				i iti.	
- '	F									
Ĺ	11057	ChemoCentryx, Inc. / Claxo Croup	Collaborative research, with execusive option for exclusive patent,	2 19 20 4	22.00 %	Not Sales		Krow-how, Option,	United State	s.
3	Edlaca:	Lid.	know-how and technology license to make, have made, use, sell,					Patent, Hesasrch.		
	Caro.		offer import and sublicense therapeutic products containing small molecule drug candidate compounds that taget chemistine					Technology		
1			receptors, to treat oblore							
	đ									
o.	i i u iu	Midatech Ltd.; MenoSol Rx, LLC/	Collaborative development to integrate nanoparticles and self-		10.00 %	Net Sales		Cross-License,	Wordwide	
a	واوهلعك	MonoSol Fix, LLC; Midwech Ltd.	a ssolving profiting technologies; with exclusive patent, know-					Know-how, Patent,	1 1 1 1 1 1 1 1	
A	100		how, process and technology prossilicenses to develop, manufacture,		10 10 1	5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	٠.	Process, Research, Technology	e feet gestelle. Gebeure	\$ - g
	10 8 8 1		and treat dis Mas					attrictività	100	2.7

Case 8:15-cv-03940-GJH Document 1 Filed 12/23/15 Page 34 of 66

11.	áririt Sárch	Cornell University, represented by the Cornell Center for Technology Enterprise and Commercialization / BioPancreate, Inc.	Exclusive patent, process and technology license to make, have made, use, have used, sell, have sold, often have othered, import, have imported and sublicense products related to commencial bacterial conversion of intestinal		2,50 %	Net Sales		Patent, Process, Technology	Wordwide
			cells to institute a latera						
12,	30,94.53	Comvita New Zee and Ltd. /	Patent and know-how license to use the "Wedlhoney" trademarks to		11.00 %	Nat Sales -		Know-how, Patent,	Worldwide
19	Spison	Denria Sciences, Inc.	make, use, import, offer, supply, seli, lease, distribute, promote and subliberese products that contain medical honey to treat, mit gate or				- ·.	Trademark	
	. C. J. R		prevent human disease, including dermal soars, souterand officials wound More	-					
200			The second secon		umaana	i			And the Committee of th
13	OUSSY Emedia	Yissum Hesearch Development Co. of the Hebrew University of	Exclusive patent, know now and technology license to develop, manufacture, market and sublicense products related to a		3,00 %	Nat Sales		Know-how, Patent, Hesearch,	Linkhown
<u>L</u> i	dr C	Jerusa'em / Intec Pharmaceutical Partnership Ltd.	bridegradable system retained in the stomach to expend me therepeut a potential of drugs baying a narrow absorption window.					Technology	
14,	90430	Onconova Therapeutics, Inc. /	Exclusive datent, know-how and process license to develop,		:20.90 %	Net Sales		Know how, Patent,	Japan,
2	Billiant	SymB o Pharmaceuticals Ltd.	manufacture, use; sell, other, import, market, distribute, promote and sublicense pharmaceutear preparations for human use which contain					Process, Supply	Korea. Republic of
	FYER		an oncology compound, in oral and injectable formulations, to treat,						
• : '	1 1 1		ameliorat More						
15.	30159	The General Hospital Corp. d/b/a	Exclusive patent, know-now, process and technical information		2.00 %	Net Sales		Know-how, Patent,	Worldwide
73	Salacit (NY)	Massanhusetta General Hospital / Viacell Endocrine Solence, Inc., a subsidiary of VaCell, Inc.	Toense to make, have made, use, sell, other, import and sublicehae products related to parcreatic stem cells for transplantation or to treat a seletes, to diagnose, treat or prevent human and animal biseases and 6					Process, Technology	
1 B.	353-66	Regenette Bagnarmaceullaats.	Explusive patient, know-how, process and technology license to use,	۳.	8,75 %	Not Sales		Know-how, Patent,	Albania, Armen a.
**	Saleriti	Ino. / Defianto Farmaceutica Lda	produce, have produced, self and sub-loanse prescription or over-the- counter pharmaceutical products and modical pevices containing the					Process, Supply, Technology,	Austria, Azerbaijan, Begium, Bo., 1978
*	3 8 km		Thymosin Beta 4 enuno ocid paplide, to treat any indication for				٠, .	Trademark	Dogram, Don,
			onternal a More				- 4		
17.	25758	Alkermes, Inc., ricensee of The	Exclusive patent and technology sublicense to make, have made, use,	•	6,00 %	Not Sales		Patent, Sublicense.	Wordwide
	Switzer;	Ohiloren's Hospital Research	loase, have sold, sell and sublicense products which utilize the C12					"eshnology	
•	(Naj)	Foundation and Chi'dren's. Haspitel, Inc. / Targeted Genetics Dorp.	aderic-associated vitus cell-line to treat and prevent pulmonary disease, infectious diseases, tumors, cardiovascular disorders, metabolic idere						
10.	24992	Senetok PLC / Argana Bioscience	Exclusive patient, copyright, proprietary: nformation, process and		12.00 %	Not Sales		Copyrights, Palent	Canado,
.72	Select	Lkd.	trademark license to use, manufacture, market, sell, distribute and sublicense a pharmaceutical product for the local treatment of erectlies		• •	. 4	٠	Process, Proprietary Info, Trademark	United States
	电声影 。		dystunction containing vascactive intestinal polypeptide and pnentols. More				11		
	Ħ					* *			
19.	Sabbe	Senetek PLC / Ardana Bioscience	Exclusive patent, bopyright, proprietary information, process and		10.00 %	No. Sales		Cocyrights, Patent.	Бигорія
W.	SMeoti SMeoti	Ltd.	trademark license to use, manufacture, marker, self, distribute and sublicense a pharmaceutical product for the local treatment of erectile dystunction containing vascactive intestinal polypeptide and phentola More		12/15 A	Had Conteat:		Process, Proprietary Info. Trademark	rembe
	得 .								
25.	2/2,007.2	Cruzeit Holland BV / Vascular	Nonexalusive patent, know-how and process license to develop, use		2.00 %	Nor Sales		Know-how, Patent,	Wordwide
7	Select:	Biogenics tild.	import, manufacture, have made, offer and self-bharmaceutical products consisting of DNA sequences obtained from the Per Cb cells.		٠.		٠.	Process	
	Ď.		using licensee's vascular largeting system platform in combination		2.2			·	
			with the gen, http://						Lagin Lida
21,.	254YO	Tel Hashomer - Medical Research.	Settlement of dispute, with patent, know-how, process, copyrights.		1.00 %	Not Sales		Copyrights, Know-	Wordwide
103	Extents'	Infrastructure and Services Etd. / Vascular Biogenics Etd.; Dron	trade names and trademark license to develop, manufacture, sell, market and sublicense products and devices related to enhancing					how, Patent; Process, Trade	
	Casti)	Harata Harata	targeting of viral vectors, expression of a general-interest in cells,					Name, Trademork	
55.	28372	UOP LLC / 28 Pharma, Inc.	Exclusive patent, process and technology license to practice.		5,00 %	Not Sales		Patent, Process	Wordwide
*3	Solvan		research, develop, make, have made, use, self, have sold, offer. Import, export, market, commercialize, exploit and austrease		11.11			Technology	
	CARAL.		products for removing toxins from bothly flutes and the gastrointestinal tract of fluma More						
				1 1 1					
	26169	University of Massachusetts / Amarontus Bioscience Holsings.	Exclusive patent license to develop, have developed, make, have made, use, have used, import, have imported, sell, have sold, and		2,00 %	Net Sales		Patent	Wordwide
23.		inc.	subligarise products and services related to so ubto MANF in partoreatic beta-cell disorders, for all fields except commercial sale of						
23.	AMAR Orio	, N. Y.	research rea More						
23.		Yeda Research and Development			3,00 %	Net Sales	1	Know-how, Patent	Word wide
Na.	OP P	ing the second of the second o	research roa 40 ro		3,00 %	Net Sales		Know-how, Patent	Worldwide

25.	eriod Edist Likki	CIMA Labs Inc. / Schwarz Pharma, Inc.	Exclusive patent, know-how, and technology license to use the "CIMA," "Duraso'v," "Pakso'v," "Oraso'v, and "Metlaba" trademarks to markst, distribute, sell and sublicanse pharmaceutical prescription products containing metaclopramide HCI, carbidopalisvodopa, baclo'an, alprax Note:		6.50 %	Net Sales	Know-how, Patent, Supply, Technology	Danada, Mexico, Puerto Rico, United States:, More
28. %	zzán Samon Čáro	Säntärus, Inc. / Gläxo Gioup Ltd.	Exclusive patent, know how and processificans to sall, offer, import and sublicense pharmaceutical products incorporating emerazors in combination with buttering agents, as capacies, powder for oral suppossion or chewapte tablets, for all human therapeutic indications, for Many		27,50 %	Nas Sales	Know-how, Palect, Process	Afghanistan, Algena, Argentina, Bahrain, Beliza, अस्त्र
27.	27360 Edect	Okohoma Medical Research Foundation: The University of Kentucky Research Foundation / Centaur Pharmaceuticals, Inc.	Exclusive patert, know-how, process and technology ilcense to make, have made, use, lease, practice, sell and subfrainse products related to spin-trapping compounds and phenylbutyl compositions, to treat exclusive tissue damage, prevent gastrio ulceration, and inhibit aging.		3.50 %	Net Sales	Knaw-how, Patent, Process, Technology	Wardwide
28.	27559 Selecti	Vanderbilk University / NaphroGenex, Inc.:	Exclusive patent and process license to make, have made, use, self, order, import and sublicense products for therepetitic application of pyricoxamine in apute read failure and other critical illnesses where the occurrence of increased exidative stress and elevated levels of store		3.00 %	Not Sales	Palent, Process	Worldwide
29.	B/521 Celepte Chiefy	Fresh Start Private Management, Inc., lidensee of Trinity Rx Solutions / JPL, LLC	Exclusive patent, know-how, process, copyrights and trademarks' sublicense to distain, market, use, se'l, and other Nathexone Implants to treat alcoholism, and to operate a related elcohol rehabilitation counseling program.	· :	10.60 %	Not Sales	Copyrights, Know- how, Patent, Process, Sublicense, Trademark	: United States
33,	Signatura Signatura Signatura Signatura	Carderbury Laboratories, LLD, successor-in-interest to Hygela Therapeutics, I censee of Yale University / Ferndale Pharma Group, Inc.	Exclusive patent sublicanse to manufacture, have manufactured, use, market, have marketed, see, have sold, import, expert and subsublicanse non-prescription products for topical administration related to carboxylic acid esters as locally acidy eatingen, for direct sales to. Most		10.30 %	No: Sales	Potent, SubFoense	Wordwide
91. 15	2000 Section	Navan Blatechnologies, Inc./ ImmunoGen, Inc.	Collaborative research program, with exclusive patent and know-how license to develop, make, have made, use, sell, offer, have sold, import, have imported and subtreense pharmaceulibal products to treat cancer in humans containing a monoclonial artiflody generated and screened 1866		5,50 %	Not Sales	Know-how, Patent, Research	Carada, Europe, Mexico, United States
92,	Zegoj Zegoj Čak	Haven Biotechnologies, Inc. / ImmunoGen, Inc.	Collaborative research program, with exclusive patent and know-how figures to develop, make, have made, use, sell, other, have sold, import, have imported and sublicense pharmaceutical products to treat cancer in himmans portaining a introclonal artifloody generated and screened		9,50 ₩	Not Sales	Know-how Patent Hasewich	Canada, Europe, Mexico, United States
33,	izance zalada Diff	Di, Falk Pharma CimbH / Coronado Biosciances, Inc.	Framework of terms for collaboration agreement with exclusive patent and know-how license to develop; use, have made, commercialize and sell pharmaceut-bal compositions containing Trichuris surs over in any formulation or delivery system, with further development of the product. Mater		1.00.95	Not Sales:	Know-how, Patent	Japan, North America, South America
34	100 Kg Vedeola (Cari)	Huigers, The State University of New Jersey / Xenogenics Corp.	Exclusive patertians process license to make, have made, use, import, put into use, distribute, self, have sold and sublicense products related to a bloabsorbable stent for interventional card-ology and peripheral vascular applications.		3.00 %	No: Sales	Palant, Process	Worldwide
35.	josej Dalesta COL	PDL BioPharma, Inc. / Alexion Pharmacavilicals, Inc.	Settlement agreement to mainufacture, use, offer, sell and import patented products related to the "Solids" humanized antibody product to treat paraxysmal recoturnal hemoglobiliums.		4.00 %	Not Sales	Uabilitios, Palent	<u> Ивгаріулі</u>
36	Triss. Selection	Schering Aktiengese bohatt / Exhala Therapeutics, Inc.	Exclusive patent, show-how, process and trademark license to develop, commercialize, use, market, sell, import, distribute and sublicense pharmaceutrosi products containing licenses from tamel for shalled use, for pulmonary hypertension in humans, with licenses to manufacture. Manufacture is the content of the product of the content o		20,90 %	Noi Sales	Know-how, Patent, Process, Supply, Trademark	United States
37.	17951 Bullett CITO	Board of Regents of The University of Toxas System, on behalf of The University of Toxas M. D. Anderson Cancer Center / Callisto Pharmaceutloals, tho.	Exclusive patent and technology license to manufacture, have manufactured, use, import, offer, sell and sublicense unspecified products for use in human or animal literapeutics, with exclusive option to improvements based on activity or structure of Tyrphosens.		5.50 %	Nat Sales	Option, Patent, Rechnology	Wordwide
28.	1765 2444: (24)	Heceptors LLG / VeriChip Corp.	Exclusive patent and technology license to make, have made, self, have sold, offer, import, export and sublicense products and services for the detection and sub-type identification at the influenza virus using the "CARA" artificial receptor, synthetic compatitor agent, and More		50.55 %	Nat Sales	Patent, Technology	Wordwide

Case 8:15-cv-03940-GJH Document 1 Filed 12/23/15 Page 36 of 66

3 <u>9</u> ,	isaa Seel	Vaxoel, Inc. / Connaught Laboratories; Inc.	Exclusive patient, technology and know-how license to man market and sub-license is parentered injectable vaccine could polyoxyethy/ane/polyoxypropylene copolymer adjuvant kno 'ORL-1005' combined with recombinant lipidated outer surprotein A 'OspA' f., Without	dring the weas	3.00 %	Nat Sales	Patent, Résearch. Tealtrology	Wočdwide	٠.
40.	0822B	Vaxçei, İnc. / Medeya Europe Lid.	Option to a co-exclusive patent, fechnology and know-how	license to	10.00 %	Net Sales	Option, Patent,	Unknown	
a	Calaco		develop, manufacture, use, distribute and sell an injectable containing the nonconic copolymer known as "CRL-1085" o	ombinea			Research		
1 . 1 .	_3 £		with fluvirina, a purified-scinada-antigen influenza virus vacci enhali. Mule	ne, to					
41,	13036	Valans Ottshore SPV II, Corp. /	Amendment to regulty agreement for patented biologic prod	uale to	9,78 %	Not Sales	Amendment, Palent	Unknowa	-
	Selecti	Blovest International, Inc.	extend maturity date of promissory note.	,,	2317.55.	7740 54474	Anticharine of 1-mant	On Circle	
(A	2.4.								
12	· water	Was to be the same of the same of			i Particular	li gale i sing i	sy fabric		
42, %1	Vəlabu .	Vicens Offshore SPV II Corp. / Blovest International, Inc.	Purchase of rights related with palented biopharmaceutical including monoclonal antibodies, peptides, infectious disease.	se and	2.12 %	Not Sales	Asset Purchase, Patent	Wondwide	
, riju:	0.5	a tijli de eel te 	cancer vaccines, autologous cancer vaccines such as for no Hodgking lymphoma and renal ce'l carcinoma, cell-based th						
	- 1	ranger und der der der der der der der der der de	stem colls, öy Maris						
13.	7.492 8	Valens U.S. SPV I. LLC / B ovest International, Inc.	Agreement pursuant to a Note Purchase to provide a revelly paterited biophiamacoutleal products, including mencolons		2.88 %	Not Sales	Palont	Worldwide	
in the			antibod as, paptides, infectious disease and pancer vaccino autorogous cancer vaccines such as for non-Hodgkins lymp remail cell carcinoma, call	s.,		-			
44.	13779	MataMorphix, Inc. / Wyelfi l/k/a	Exclusive patent and technology cross-license with royally-		2,00 %	Net Sales	Cross-License,	Unknown	
***	Colecti	American Home Products Corp. through Genetics Institute, LLC	how license to make, have made, use; Import, market, offer, the "GDF-B" TOF-B Factor formulations, antibodies, receptor	vs.			Know-how, Patent, Techniclogy		
147		f/Wa Genetica institute, Inc.	anitames molecules, pharmaceutical products, anitagonists, and mou. House	vaccines					
45.	7980	Roger Harris; Mark Dunnelt,	Exclusive patent and know-how license to manufacture, use	aall savi	6.00 %	Mas Galler	tendos actorios y y 1 k		i
23	ulelseu	individuals / Natural Allematives	transfer products related to bota alanino, creating, and Links	tidine to	5.00 %	Not Sales	Know-how, Palent-	Worldwide	
13.1	<u>ز</u> ،	International, Inc.	enhance the work capacity of musices, for use in humans, d horses and camels.	ogs.					
	ø:								
1B.	C421	ALW Partnership, a partnership of	Exclusive patent liberree to manufacture, have manufactured	, use and	6.20 %	Net Sales	l'alent	Wordwide	4
2	Selecti	Crarg Aronchick, William Lipshutz and Scott Wright / Panax	sell solid dosago forms of sod um prosphate selfs for use or purgetive or laxative composition and method.	a co'onio	# Time			**************************************	
	5_9 K_	Pharmaceutical Co. Ltd.			n forsk forsk Forsk forsk			H 1	
									.e
47 23	(112) soleot 3133	The Schoos Research Institute / Stemcells, Inc.	Exclusive patent, know-hew, process and sechnology licens- have made, use, have used, sell, have sold, imports have im- export, have excorded, distribule, have distributed and subli- products related to pancreatio stem and progenitor sells for appl., Nove.	ported, cense	2,00 %		Know-how, Patent, Process, Technology	. Worldwide	
48.	256	Aled D, Keth, Ph.D., Individual /	Exclusive patent license to develop, menufacture, use, mark	et and	10.00 %	Net Sales	Patent	Worldwide	
24	STATE	Watson Pharmacauticals, Inc.	sell pharmacautical formulations consisting of high density of form designed to pass through the Ol tract slower than is ge				· In the second		
: 1	() E (expected.						
				· ·		12 11.	the state of the s		
49.	Schot:	Anutech Pty. Ltd. / Prax's Pharmacousticals Inc.	Exclusive eatent, trademarks, know-how and oppyrights lice make, use and sell broducts released to phosphosugars for the		10,00,%		Copyrights, Know- hov, Patent,	Wordwide	
/3 / Ti	A RELI		of inflammatory skin conditions. Inflammation resulting from abdominal or perviousness, and equilar inflammation, and extension applications. More	coluding			frademark		
60.	633	Eurand America, inc. / Globa	Exclusive patent, know-now, process and technology license	e in use:	5.00 %	Not Sales	Know-how, Patent,	United States	
W.	Lelcon	Pharmaceutical Corp.	offer and sell finished dosage forms of gastro-protected pun pharmaceutical products containing pancreally enzymes in	creatin	2.40 20		Process, Supply, Technology	Outlier States	
-1,71			sustained release formulation having USP Lipase contents of and semi-exclusions.		ji kurés		:៤ភាព លើវិ	- 1	i
-	Ø.								:
iyat Silay					0				
Untit	elso	: (10.00 - 1	1.00 3.00 6.00	6.0 4		6,25	10.00 8.77	######################################	:
Filters	ea (9	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1.00 3.06 6.00	7.12	e de la composition della comp	6.25	10.00 5.07	20,00	
State	stical inte	rval	and the second of the second o		**********	e e e e e e e e e e e e e e e e e e e			

DASHBOARD SEARCH & SEARCH BOARD



Folder: Cecil (14) - RoyaltyTableauTM 🔞

	Kriow-how, Patent	Copyrights, Know- how, Patent. Process; Trade Name, Trademark	Súblicense, Trade Name	Patent, Research, Technology	Option, Patent, Research	Copyrights. Trademark
Download	æ	2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 2		Yes	Ş
Folder	2.00 % Net Sales	1.00.9% Net.Sales	10.00°36. Net Salés	8.00 % Net Sales 6.00 %	16,00°% Net.Sales. 6,00°%	8,00 % Net Sales
neris " The Data	TRANSLATE ROYALTY PATER Nonexclusive patent, know-how and process 2:00 % Rennes to develop, use, import, manufacture, heve made, offer and set pharmaceutical products consisting of DNA Sequences obtained from the Per.C6 cells using dicenses is vascurar targeting system platform in combination with the	treat cancer in numars using an adenovitat vector, including therapeutic gene sequences, but not serving as a vaccine. Sequencer of dispute, with patient, know-how, process, copyrights, trade names and trademark floerise to develop, manufacture, self, market and sublicense products and devices retained to enhancing targeting of viral vectors, expression at a gener-of-inferest in cells, treatment.	Exclusive sublicense to use the "vatican Observatory" trade name and logo to design, manufacture, self, distribute and advertise religious themed products for funerary use, including urns, oremation keepsakes, caskets, casket yells, purlar yealing, burlat hiches, columbariums, monuments and markers, prayer catcle, guest signature books, and candles.	Exclusive patent, technology and know-how. Beense to manufacture, market and subliceitse a parentaral injectable vaccine domaining the polypxyjethylenet/polyoxypropylene cobolymer adjuvant known as "ORL-1003" combined with recombinant lipidated outer surface protein A "OspA" f 8/pre-	Option to a co-exclusive patent, technology and know-how ticense to develop, manufacure, use, distribuce and sell an injectable vaccine containing the nonicorpolymer from as "CRE_1 tobe" combined with furning, a purified surface—inject influence avives vaccine, to sehance the immunie response in humans invough Phase I human clinical trials.	Nonexclusive (cense to use the The Cat Fanciers' Association' trademarks copyrights, and designs to intaminature, distribute, promote and sell a funerity line of branded ums, though
) × All'Agreements	Crucell Hollarid BV/ Vascular Biogenics Ltd.	Tel Hashomer- Medical Research, Idrastuciure and Services Ltd. / Vascular Biogenics Ltd.; Dror Hatats	Gruppo Santony, LLC/ Gernal Image	Vaxoel, inc. f Cornaugh Laboratories, inc.	Vaxei, inc. /Wedeva Europe Ltd.	The Cat Fanciers Association, Inc. / Eternal Image, Inc.
" Net Sales % (14)	VE DATE 2011 20	200	5 B007	9.	C. 19861	1/31/2007. 2.9
Royalty Tableau	0 REK. CEFFECTIVE DATE 1. 28-77 4/16/2011 0 Reason:	2. 28470 02/03/2013 @ Resport.	3. 1831(0 06/10/2009 (6 78/4/2007)	4. 16244 6/4/1995 @ Romesic.	5. 16238. 10/12/1995	6. 15990 1/31/20 (3) Netroor:

Có. / Eternal Image: Inc. Có. / Eternal Image: Inc. University name, trademarks, and indicia to market and self intermortal products such as caskets, trns, and vaults. 9. 16906 8/29/2007 3.33 CBS Consumer Nonexclusive copyright floense to use the "Star 10.00 % Net Sales: Yes Copyright floense to use th	oyrights, iemark oyrights, demark endment, oyrights, demark
Properties, Inc. / Eternal American and National Leagues, Major League Cop Reason: Image Inc. Baseball, and individual baseball clubs' Trad trademarks, copyrights, and logos to manufacture, distribute, promote, advertise and sell caskets, urms, headstones and vault covers	oynghts.
Corp. / Blovest biologic products to extend maturity date of 5.96 %	endment, Pati
Beascon International, Inc. promissory note.	
12. 14929 12/10/2007 Parpetual Valens Offshore SPV II Purchase of rights related with patented 2,12 % Nat Sales No Asset Diopharmaceutical products, including Pate international, inc. Carp disease and cancer vaccines, autologous cancer vaccines such as for non-Hodgkins lymphoma and renal cell-based therapies, atem cells, cy., More	et Purohase, ent
13. 14928 12/10/2007 Perpetual Valens U.S. SPV1, LLC / Blovest International, Inc. Peason: Agreement pursuant to a Note Purchase to 2.88 % Net Sales No Pate products, Including monoclonal antibodies, peptides, infectious disease and cancer vaccines such as for non-Hodgkins lymphoma and renal cell carcinoma, cell More	ant
Wyeth ffk/a American with royalty-free know-how license to make, have Kno	ss-License, ov-how, Pater hnology
Unflittered 1,00 2,09 8,00 6,82 7,02 10,00 3,89	12,00
Filtered 3 14 1.00 2.09 8.00 6.82 7.02 10.00 3.89 Statistical interval	12.00

Contact | Privacy Policy | Log of



DATABAGE L'ADMIN L'OCNTACT : LOG OFF

DASHROARD

SEARCH

A MAY ACCU

FEATURES .

Folder: Cecil (14) - RoyaltyTableauTM o

Royalty Tableau «	Net Sales %	(14) *	All Agreements		Filter Dota	Folder		→ Download	
							rá Gur	itiinivissiisissi vas	111
	TRANSLATE	ROYALTY RATE							
exclusive patent, know-how an nee to develop, use, import, ma p made, offer and sell pharmacu funds consisting of DNA sequer in the Per.C6 cells using licenser etiling system platform in combi ome of a serotype 5 human ade cancer in humans using an ad or, including therapeutic gene not serving as a vaccine.	mufacture; eutical nces obtained o's vascular nation with the enovirus, to lenovirus	2,00 %	Net Sales -	Na	Know-how, Patent, Process	Pharmaceutical 2834 & Biotech	325412	License Fee, Milestone Payment	Worldwid
lement of dispute, with patent, ness, copyrights, trade names s nse to develop, mamifacture, se icense products and devices re ancing targeting of viral vectors gene-of-interest in cells, treatn	and trademark all, market and etated to , expression	1.00 %	Net Sales	No	Copyrights, Know- how, Patent, Process, Trade Name, Trademark	Pharmaceutical 2834 & Blotech	325412	Sublicense Royalty	Worldwid
usive sublicense to use the "Va ervatory" trade name and logo jufacture, sell, distribute and ad ipus themed products for funer uding urns, cremation keepsaks ket vells, burial vaults, burial nic mbaritums, monuments and ma is, guest signature books, and is	to design, ivertise iary use, es, caskets, ihes, arkers, prayer	10.00 %	Net Sales	No	Sublicense, Trade Name:	Consumer 3990 Products		Minimum Royalty, Sublicense Royalty	Worldwid with Exception
usive patent, technology and k ise to manufacture, market and interal injectable vaccine conta oxyethylene/polyoxypropylene vant known as "CRL-1005" col imbinant lipidated outer surfact oA" I.,, where	I sublicense a ining the copolymer mbined with	8.00 % 6.00 %	Net Sales	Yes	Patent, Research, Technology	Pharmaceutical 2836 & Biotech	325414	Milestone Payment, Other Payments	Worldwid
on to a co-exclusive patent, te- y-how license to dévelop, man ibute and sell an Injectable vac alising the nonlonic copolymer1005' combined with fluvirin toe-antigen influenza virus vac ince the immune response in h ugh Phase (human clinical trial	ufacture, use, cline known as a, a purified- cine, to umans	15,00 % 6,00 %	Net Sales	Yes	Option, Patent, Research	Pharmaceutical 2836 & Blotech	325414	Upfront Payment, Other Payments	Unknow
exclusive license to use the 'Ti liers' Association' trademarks, designs to manufacture, distrik sell a funerary line of branded ' a retailers and funeral homes.	copyrights, tute, promote	9,00,96	Net Sales	No.	Copyrights, Trademark	Consumer 3990 Froducts		Uptront Payment, Minimum Royalty	Canada, United States

Case 8:15-cv-03940-GJH Document 1 Filed 12/23/15 Page 40 of 66

ersity name, trademarks, and Indicia to Trademark Products. Ufacture, advertise, distribute and sell portion of the Total products such as caskets, urins, and the Total products such as caskets, urins, and the Total products such as caskets, urins, and the Total products of the Total	inited tales ustralia, anada, urope,
Trademark to distribute, promote, Trademark Products, C. Ulacture and self caskets, urns, monuments Broadcasting Statistics of unaral homes.	anada, urope,
	apan, New ealand, Ink., More
	nited tales
ndment to royalty agreement for patented 9.46 % Net Sales Yes Amendment, Patent Pharmaceutical 2834 325412 Langle products to extend maturity date of 5.96 % & Blotech sissory note,	nknown
hase of rights related with patented 2:12 % Net Sales No Asset Purchase, Pharmaceutical 2834-325412 W harmaceutical products, including Patent & Blotech octional antibodies, peptides, infectious see and cancer vaccines, autologous cancer sires such as for non-Hodgkins lymphoma ranal cell carcinoma, cell-based therapies,) cells, cy., More	oldwide
ement pursuant to a Note Purchase to 2.88 % Net Sales No Patent Pharmaceutical 2834 325412 Welde a royalty for patented blopharmaceutical & Bloteich & Blo	orldwide
usive patent and technology cross-license 2.00 % Net Sales No Cross-License, Pharmaceutical 2834 325412 Un royalty-free know-how license to make, have Know-how Patent, & Blotech Becting Technology F-8* TGF-B Factor formulations, antibodies, pharmaceutical ucts, antisonies and mo More	nknown
\$1istered: 1.00 2.09 8.00 8.82 7.02 (0.00 3,89	12,00
litered	12.00

tatistical interval

Contact | Privacy Policy | Log off



DATABASE | ADMIN | CONTACT | LOGIOTE

MY ACCOUNT Y FEATURES Y

Search Results (2000) 0

Industry:

Pharmaceutical & Blotech Refine Search

Sub-Industry:

Gastro Intestinal

Agreement Type:

Patent Refine Search

Agreement Type Excluding: Franchise, Asset Purchase, Amendment Refine Search

Royalty Base:

Net Sales Refine Search

Related Parties:

Exclude

(3983 Hits)

(123 Hits)

(107 Hits)

(83 Hits)

(79 Hits)

(76 Hits)









We found 76 agreements matching your search criteria.

112 -

1, (1) (1)	31128	2836	The Penn State Research Foundation / Innovive Pharmaceuticals, Inc.	2005	20	Exclusive patent and know-how license to make, have made, use, léase, sell, practice, have practiced and sublicense products and processes related to optoid growth factor, taxanes, and gemotiable to treat cancer, f More	ijo.00 %	Net Sales	Gopyeghts.
2 ,	31096	2834	ARYx Therapoutics, Inc. / Procter & Gambie Pharmaceuticals, Inc.	2006	20	Exclusive patent, know-how, process and fechnology license to exploit, make, have made, import, use, sell, offer, dispose of, research, develop, manufacture, formulate, export, commercialize, promote, distribute and, More	8.00 %	Net Sales	Соругама
3, (1)	31064 57	2834	ARYx Therapeutics, inc. / Procter & Gamble Pharmaceuticals, inc.	3008	.50	Exclusive patent, know-how, process and technology license to exploit, make, have made, import, use, sell, offer, dispose of, research, develop, manufacture, formulate, export, commercialize, promote, distribute and More	20.00 %	Net Sales	Copydanta
4. ±1	31091	2834	Renovis, Inc. / Pfizer Inc.	2005	20	Exclusive patent, know-how and technology license to manufacture, use, sell, offer, import and aublicense VH-1 antagonists, either as a single agent or in combination, to freat human diseases or disorders, including Notes	12.00 %	Net Sales	Copyrgins
5. ([])	aines (1)	2834	ChemoCentryx, Inc. / Glaxo Group Ltd.	2006	20	Collaborative research, with exclusive option for exclusive patent, know-how and technology license to make, have made, use, sell, offer, import and sublicense therapeutic products containing small molecule drug can More	18,00 %:	Net Sales	Copyrights
6.	31077	2834	ARYx Therapsuilos, Inc. / Procter & Gamble Pharmaceuticals, Inc.	2006	20	Exclusive pateitt, knew-how, process and technology license to exploit, make, have made, import, use, sell, offer, dispose of, research, develop, manufacture, formulate, export, commercialize, promote, distribute and More	25.00 %	Net Sales	Сбрувізіна
7. iji	31067 (j)	2834	ChemoCentryx, Inc. / Glaxo Group Ltd.	2006	20	Collaborative research, with exclusive option for exclusive patent, know-how and technology license to make, have made, use, self, offer, import and sublicense therapeutic products containing small molecule drug can More	22,00 %	Net Sales	Сорундата



DATABASE I ADMIN I CONTACT I COGOTE

MY ACCOUNT V FEATURES V

	earc		

Industry:

Pharmaceutical & Biotech Refine Search

Sub-Industry:

Gastro Intestinal

(3983 Hits) (123 Hits)

Agreement Type:

Patent Refine Search

Agreement Type Excluding: Franchise, Asset Purchase, Amendment Refine Search

(107 Hits)

(83 Hits)

Royalty Base:

Net Sales Refine Search

(79 Hits) (76 Hits)

Related Parties;

Exclude





We found 76 agreements matching your search criteria.

);;; ~

tv O	a1128	2835	The Penn State Research Foundation / Innovive Pharmaceuticals, Inc.	2005	20	Exclusive patent and know-how license to make, have made, use, lease, sell, practice, have practiced and sublecense products and processes related to opioid growth factor, taxanes, and genetabline to freat cancer, f Mora	10.00 %	Not Sales	Copyrights
2.	31696 - 5 7	2834	ARYX Therapeutics, Inc. 7 Prooter & Gamble Pharmaceuticals, Inc.	2006	20	Exclusive patent, know-how, process and technology license to exploit, make, have made, linport, use, sell, offer, dispose of, research, develop, manufacture, formulate, export, commercialize, promote, distribute and**********************************	6.00 %	Net Sales	Copyrights
3. ©	81994 5 7	2834	ARYx Therapeutics, Inc. / Procter & Gamble Pharmaceuticals, Inc.	2006	20	Exclusive patent, know-how, process and lechnology license to exploit, make, have made, import, use, sell, offer, dispose of, research, develop, manufacture, formulate, export, commercialize, promote, distribute and More	20.00 %	Net Sales	Copyrights
4.	31091	2834	Renovis, Inc. / Pfizer Inc.	2005	20	Exclusive patent, know-how and technology ilcanse to manufacture, use, sell, offer, import and sublicense VR-1 antagonists, either as a single agent or in combination, to treal human diseases or disorders, including More	12.00 %	Net Sales	Copyeghts
5. (*) ;;;;	31085 Ö! 5 7	2834	ChémoCentryx, Inc. /- Glaxo Group Etd.	2006	20	Collaborative research, with exclusive option for exclusive patent, know-how and technology license to make, have made, use, self, offer, import and sublicense therapeutic products containing small molecule drug can More	18.00 %	Nët Sales	Copyeghts
8.	31677 53	2834	ÄRYX Therapeulics, Inc. / Procter & Gamble Pharmaceuticals, Inc.	2006	20	Exclusive patent, know-how, process and technology license to exploit, make, have made, import, use, self, offer, dispose of, research, develop, manufacture, formulate, export, commercialize, promote, distribute and More	25.00 %	Net Sales	Copyrights
7: (3) [1]	31067	2834	ChemoCentryx, Inc. / Glaxo Group Ltd;	2006	20	Collaborative research, with exclusive option for exclusive patent, know-how and technology license to make, have made, use, sell, offer, import and sublicense the apeutic products containing small molecule drug can., More	22.00 %	i∛et Saleş	Copyrights

Case 8:15-cv-03940-GJH Document 1 Filed 12/23/15 Page 43 of 66

8.	31038	2834	Midatech Ltd.; MonoSol	2008	20	Collaborative development to integrate nanoparticles and self-	10.00 %	Net Sales	Copyrights
17			Rx, LLC / MonoSol Rx, LLC; Midatech Ltd.			dissolving oral thin film technologies, with exclusive patent, know- how, process and technology cross-licenses to develop,			
1			ELO, MOBICON ELO.			manufacture, commercialize and, Mera			
9.:	30972	2834	Cornell University,	2011	20.	Exclusive patent, process and technology license to make, have	2.50 %	Net Sales	Copyrights
\subseteq			represented by the Cornell Center for			made, use, have used, sell, have sold, offer, have offered, import; have imported and sublicense products related to commensal			
74.1			Technology Enterprise		•	bacteria as signal mediat More			
			and Commercialization / BioPancreate, Inc.						
			an ar ar gairt an a					process	were and the state of
10,	30841	384)	Comvita New Zealand Ltd. / Derma Sciences,	5010	Perpetual	Patent and know-how license to use the "Medihoney" trademarks to make, use, import, offer supply, sell, lease, distribute, promote and	11.00 %	Net Sales	Copyrights
			Inc.			sublicense products that contain medical honey to treat, mitigate or			
Lists.					1 1	prevent hu More			
ii.	30861	2834	Yissum Research	2000	20	Exclusive patent, know-how and technology license to develop,		No. on	
		2004	Development Go, of the	.2000	٥٤	manufacture, market and subficense products related to a	3.00 %	Net Sales	Copyrights
0	Ö		Hebrew University of			blodegradable system retained in the stomach to expand the			
Į PE			Jerusalem / Intec Pharmaceutical			therapeutic potential of drugs having More			
			Partnership Ltd,						
12.	30430	2834	Onconova	2011	20	Exclusive patent, know-how and process license to develop,	20,00 %	Net Sales	Copyrights
:	2012		Therapeutics, Inc. / SymBio		i ji shi	manufacture, use, sell, offer, import, market, distribute, promote and sublicense pharmaceutical preparations for human use which			
1.			Pharmaceuticals Ltd.			contain an encology compou Mare			
	200				-11				19 19 1 1 E
13,	30163	8731	The General Hospital	2002	20	Exclusive patent, know-new, process and technical information	2.00 %	Net Sales	Copyrights
<u>"</u> j"			Corp. d/e/a Massachusetts General			license to make, have made, use, self, offer, import and sublicense products related to pancrealic stem cells for transplantation or to			
1			Hospital / Viaceli			real diabeles, t., Mom			
			Endocrine Science, Inc., a subsidiary of						
			ViaCell, Inc.			N.			
14,	29344	2834	RegeneRx	2004	20	Exclusive patent, know-how, process and technology license to use,	8,75 %	Net Sales	india
101			Biopharmaceuticals,			produce, have produced, sell and sublicense prescription or over-			. Presentation
. KVII		344	Inc. / Defiante Farmaceulica Lda			the-counter pharmaceutical products and medical devices containing the Thymosin Bet More			Copyrights
15,	29135	2836	Alkermes, Inc., licensee	1999	20	Exclusive patent and technology sublicense to make, have made,	6.00 %	Net Sales	Copyrights
1 . }			of The Children's Hospital Research			use, lease, have sold, sell and sublicense products which utilize the C12 adeno-associated virus cell-line to treat and prevent pulmonary			
- 4			Foundation and			disease, intec.,, More			
			Children's Hospital, Inc. / Targeted Genetics						
			Corp.						
16,	28862	2836	Senetek PLC / Ardana	2004	20	Exclusive patent, copyright, proprietary information, process and	12,00 %	Net Sales	Copysights
. O	B		Blasolence Ltd.			trademark floorise to use, manufacture, market, soil, distribute and			
i i SasAr						sublicense a pharmaceutical product for the local treatment of erectile dysfuncti More			
		is de la							
17.	28856	2836	Senetek PLC / Ardana	2004	20	Exclusive patent, copyright, proprietary information, process and	10.00 %	Net Sales	Copyrights
(<u></u>)	5		Bioscience Ltd.			trademark license to use, manufacture, market, sell, distribute and sublicense a pharmaceutical product for the local treatment of			
3.5						eracille dystuncti Man			
·						rend i don miskop, do o nijetovi vijetenio i ili ve mine ili			5 1 5 11 1
16.	28312	2834	UOP LLC / ZS Pharma, Inc.	2011	20	Exclusive patent, process and technology license to practice, research, develop, make, have made, use, sell, have sold, offer,	6,00 %	Net Sales	Copyrghts
i i						Import, export, market, commercialize, exploit and sublicense		100	
1.87						products for removing toxi More	٠		
113	.da.een	nio 4	t in house the ne	nace	20	Fireholis advice linears to desirthic basis disavours being	2000		
19:	28159.	2834	University of Massachusetts /	2013	20	Exclusive patent license to develop, have developed, make, have made, use, have used, import, have imported, sell, have sold, and	2.00 %	Net Sales	Copyrights
(C+			Amarantus Bioscience			sublicense products and services related to soluble MANF in			
115			Holdings, Inc.	and a contract of the contract	ngang kecamatan di	pandréatió, betá-céli diso Moje: «Nell'100 la cum leterno de congras e page sus en a mojos page susante e que	ari tara a sa		
			egran in der einer sig ib-	and the facility of the	1-12/10/97		Pater New York	ub-colored by the	okrimich bildes - €

Case 8:15-cv-03940-GJH Document 1 Filed 12/23/15 Page 44 of 66

		;		a jajoje akstra		n de la compresentación	an elektrik ili.	,	
20.	27906	2834	OlMA Labs Inc. / Schwarz Pharma, Inc.	2001	20	Exclusive paterit, know-how, and technology ildense to use the "CIMA," "DuraSoly," "PakSoly," "OraSoly" and "Meltaba" trademarks	6.00.%	Net Sales	Copyrights
	Ľ.					to market, distribute, sell and sublicense pharmaceutical prescription			
7.7						products contain, More			
21,	27881	2834	Santarus, Inc. / Glaxo	2007	Perpatual	Exclusive patent, know-how and process license to set, offer, import	27.50 %	Net Sales	Javier -
Ç1		400 (Group Ltd.		4 - 4 É - 1	and aublicense pharmaceutical products incorporating omeprazole in			11042014
A. Ju						combination with buffering agents, as capsules, powder for oral suspension or More			Copyrights
3.44									
22,	27863	2834	Oklahoma Medical	1992	- 20	Exclusive patent, know-how, process and technology license to	3.00 %	Net Sales	Copyrights
400			Research Foundation; The University of			make, have made, use, lease, practice, sell and sublicense products related to spin-trapping compounds and phenyibutyl compositions,			
i Hell.			Kentucky Research			to heat oxidative t √cre			a sek kili
11.	er fee		Foundation / Centaur Pharmaceuticals, Inc.				161		
	and a			0000	20	Carticles werent and process Report to water trade words 1550 poll.	9 90 94	Mai Cales	Para - Para
23,	27559	2834	Vanderbill University / NephroGenex, Inc.	2006	20	Exclusive patent and process license to make, have made, use, sell, offer, import and sublicense products for therapeutic application of	3,00 %	Net Sales	Copyrights
	Ü					pyridoxamine in acute renal fallure and other critical illnesses where the occ Mare			
5/18 2/18						BR OPPUT HARE			
24.	25985	2834	Raven Biotechnologies,	2001	20	Collaborative research program, with exclusive patent and know-	5.50 %	Net Sales	Copyeghts
	6		Inc. / ImmunoGen, Inc.		·	how license to develop, make, have made, use, sell, offer, have sold,	* * *		
August 1						Import, have imported and sublicense pharmaceutical products to treat cancer in hu More			
- 11									
25.	25943	2834	Raven Blotechnologies.	2001	20	Collaborative research program, with exclusive patent and know-	9,50 %	Net Sales	Copyrights
D	∂		ino. / immunoGen, inc.			how license to develop, make, have made, use, self, offer, have sold, import, have imported and sublicense pharmaceutical products to			
300						treat cancer in hu.,. bloss			
				÷		Note that are a second transfer of the second		* * * * *	el en la ge
26.	28640	2836	Onyx Pharmaceuticals, Inc. / Warner-Lambert	1999	20	Collaboration program with exclusive patent license to make, have made, use, offer, sell, have sold, import and sublicense products	13.00 %	Net Sales	
<u> </u>		- 1	Go.			consisting of a genetically engineered adenovirus that replicates in			
	· · · · ·					and killis cano More	11		
	and had	 معتمد	0	dána.	án.	Exclusive patent, know-how, process and fechnology license to	24.00 %	Net Sales	Javiet.
27.	23687	2834	Novacea, Inc. / Schering Corp.	2007	20	develop, make, have made, use, commercialize, market, promote,	24.00 78	1401 02103	11042014
F)						distribute, offer, sell, import, export and sublicense pharmaceutical products containing More			Miguel
}49 1				.,.		producto correspond to assess			
28.	23828	384t	Tri-Point Medical Gorp.	1996	20	Exclusive patent, know-how and process license to use, market,	5.00 %	Net Sales	
iai.			/ Ethicon, Inc.		2	advertise, promote, distribute, sell and sublicense the "TraumaSeal"			
i ayan						topical ilquid suture, which is a non-absorbable, formulated, 2- octylcyanoacrylate Mora			
29.	วัวกรณ	2836	Organogenesis Inc. /	1996	20	Exclusive patent license to use, import, sell, offer and sublicense the	12.00 %	Net Sales	
(<u></u>).			Sandoz Pharma Ltd.			"Grafiskin" skin and tissue equivalent products, designed to mimic the structure and function of human skin, intended for use in venous			
11.3						stasts More			
		1112	The state of the s			The state of the sta	a series as a		
30.	22778	2834	Dr. Falk Pharma GmbH; Overned GmbH /	2012	50	Collaboration agreement, with exclusive patent, process and know- how license to use, develop, commercialize, self, offer, import, and	1.00 %	Net Sales	
CF	. Ti		Coronado Biosclences,			sublicense pharmaceutical products containing Trichuris suis ova as			
/**			inc.			the active In More:			
		. Denot	and the second of the second o					ecilir A	all markets and the second
51.3	j== (82)	(56) E			1 2 3 Next >		Rows to	diablay: 30 \$
		a C							
			요. 경우 교통 19 분들하는 프로토니다						

9.201

34.000

1,000

5,000

7.000



DATABASE + ADMIN + CONTACT + LOG OUT

DASHBOARD

GERC!

MY ACCOUNT

FEATURES V

Search Results . @

15927, 18010, 15906, 15990, 15905, 15928, 16228, 16244, 13775, 14928, 14929, 15020, 28471, 28470

(14 Hits)

(14 Hlts)

Royalty Base: Net Sales Refine Search







Cause to Mary Colder

Wei fo	ound 14	agreer	nents matching your se	earch oriteria.							111 -
1. ① ② ② ② ② ② ②	28471	2834	Crucell Holland BV / Vascular Biogenics Ltd.	2011	20	Nonexclusive patent, know-how and process license to develop, use, import, manufacture, have made, offer and sell pharmaceuscal products consisting of DNA sequences obtained from the Per.C6 cells using licensee's vascular targeting system platform in combination with the genome of a serotype 5 human adenovirus, to treat cancer in humans using an adenoviral vector, including therapeutic gene sequences, but not serving as a vaccine.	2.0	0%	Net Salas	Know-how, Patent, Process	Worldwid
	28470	2834	Tel Hashomer - Medical Research, Infrastructure and Services Ltd. / Vascular Biogenics Ltd.; Dror Harats	2014	20	Settlement of dispute, with patent, know-how, process, copyrights, trade names and trademark floense to develop, manufacture, sell, market and sublicense products and devices related to enhancing taggeting of viral vactors, expression of a gene-of-interest in cells, treatment with VB-201- PAF-like homologs, oxidized phospholipids, endouhellal cell specificity, anti-anglogenic adenovirus vectors, and treatment of ischemia, atherosclerosis, vascular disease, inflammatory disease, cancer, gliobiastoma, wound healing, and tumor related conditions.	1,0	0%	Net Sales	Copyrights, Know- how, Patent, Process, Trade Name, Trademark	Worldwid
3.	18010	3980	Gruppo Santony, LLG / Eternal Image	2009	5	Exclusive sublicense to use the "Vatican Observatory" trade name and logo to design, manufacture, sell, distribute and advertise religious themed products for funerary use, including urns, cremation keepsakes, caske., Mare	10.0	00 8 6	Net Sales	Sublicanse, Trade Name	Worldwid with Exception
4.	16244	2836	Vaxcel, Inc. / Connaught Laboratories, Inc.	1995	15	Exclusive patent, technology and know-how license to manufacture, market and sublicense a parenteral injectable vaccine containing the polyoxyethylene/polyoxypropylene copolymer adjuvant known as "CRL-1005" combined More		0 % 10 %	Net Sales	Patent, Research, Technology	Worldwid
5; O	16226	2836	Vaxcei, Inc. / Medeva Europe Ltd.	1995	2	Option to a co-exclusive patent, technology and know-how license to develop, manufacture, use, distribute and self an injectable vaccine containing the nonionic copolymer known as "CRL-1005" combined with fluviring More		00 % 10 %	Net Salas	Option, Patent, Research	Unknown

Case 8:15-cv-03940-GJH Document 1 Filed 12/23/15 Page 46 of 66

, 15990 39	90 The Cat Fanciers Association, inc. / Eternal Image, Inc.	2007	2,9	Fanciers' Associa	ise to use the 'The Cat lion' trademarks, copyrights, inviacture, distribute,	B.00 %	Net Sales	Cepyrights, Trademark	Canada, United States
					i funerary line of branded s retailers and funeral				
. 15928 . 39	90 The American Kennel Club / Eternal Image, LLC	2005.	3.†	Kennel Club" trad manufacture, disti funerary line of Ak	nse to use the "The American emarks and copyrights to Route, promote arid sell a IC branded urns, through pel s retallers and Int More	11.	Net Sales	Copyrights, Trademark	Canada, United States
15927 39	90 Collegiate Licensing Co. / Eternal Image Inc.	Unknowa	Unknown	University name, t manufacture, adv	nse to use the Louislana Stat rademarks, and indicia to otise, distribute and sell e such as caskets, urns, and	e 8.00 %	Net Sales	Copydghts, Trademark	United States
, 15906 39	90 CBS Consumer Products, a division of CBS Broadcasting Inc. / Eternal image	2007	3,331	Trek" trademark to manufacture and	yright license to use the "Sta odistribute, promote, sell caskets, urns, aults to funeral homes.	ir 10.00.%	Net Sales	Copyrights, Trademark	Australia, Canada, Europe, Japan, Ni Za, Mon
), 15905 39	90 Major League Baseball Properties, Inc. / Eternal Image Inc.	2007	**************************************	American and Nat Baseball, and Indi trademarks, copy	nexclusive license to use the lonal Leagues, Major League vidual baseball clups! lights, and logos to libute, promote, adventse an		Cella Pell	Amendment, Copyrights, Trademark	United States
). 15020 28	34: Valens Offshore SPV II, Corp. / Blovest International, Inc.	2008	Unknown		ralty agreement for patented to extend maturity date of	9.46 % 5.96 %	Het Sales	Amendiment, Patent	Unknown
2. 14928 28	34 Valens Offshore SPV II Corp. / Biovest International, Inc.	2007	Perpetual	blopharmaceutica monoclonal antibo disease and canc	related with patented i products, Including odles, peptides, infectious er vaccines, autologous uch as for non-Hodgkins. ore	2.12 %	Net Sales	Asset Purchasé, Patent	Worldwid
) [j] 	94 Valens U.S. SPV I, LLC / Bloyest International, Inc.	2007	Perpetual	provide a royalty l biopharmaceutica monoclonal antibo	I producis, including odles, peptides, infectious er vaccines, autologous	2,88:96	Net Sales	Patènt	Worldwid
1. 33776 28	MetaMorphix, Inc. / Wyeth I/Wa American Home Products Corp. through Genetics Institute, LLC. I/Wa Genetics Institute, Inc.	2002	20.	with royalty-free k have made, use, i the "GDF-8" TGF-	ind technology cross-license now-how license to make, mport, market, offer, and sell 9 Factor formulations, ors, anitsense mole More		Net Sales	Cross-License; Know-how, Patent, Technology	Unknown
_ (122) [#	(59) ©	antrial (See			보세력 및 1950년, 1년 개 년			Rows to display	30 7
						sol arivigo cario gener			
- Z						0			

Contact | Privacy Policy | Log off



DATABASE ! ADMIN ! CONTACT | LOG OFF

DASHBOARD

SCARCH

MY ACCOUN

FEATURES

Search Results

Royalty Base: Net Sales Refine Search

15927, 18010, 15906, 15990, 15905, 15928, 16228, 16244, 13775, 14928, 14929, 15020, 28471, 28470

(14 Hits)

(14 Hits)

= 12212n (5111111)







ave to New Folder

We found 14 agreements matching your search criteria.

		and remain to the area.	andge to the contract of the contract					
	•							
iexcitisive patent, know-how and process ise to develop, use, import, manufacture, a made, offer and sell pharmaceutical lucts consisting of DNA sequences three from the PerC6 cells using licensee's bular targeting system platform in iblination with the genome of a serotype 5 ran adenovirus, to treat cancer in humans g an adenoviral vector, including apeutic gene sequences; but not serving as occine.	2.00 %	Net Safes	Know-frow, Patent, Process	Worldwide	'No	Pharmaceutical & Blotech	Cancer Cardiovascular, Genetic, Vaccines	License Fee, Milestone Payment
Secretary and an experience of the second secretary and the second second second second secretary and the second seco								the state of the state of
lement of dispute, with patent, know-how,	1,00 %	Net Sales	Copyrights, Know-	Worldwide	No	Pharmaceutical	Cancer,	Sublicense Royalty
iess, copyrights, trade names and	es de la companya de		how, Patent,			& Blotech	Cardiovascular,	
amark ficense to develop, manufacture,			Process, Trade		the transfer of the same	the second to be a second	Genetic, Cold &	
market and sublicense products and	당시 기계가 심어	e distriction and	Name, Trademark				Flu,	
ces related to enhancing largeting of viral	And the second second	100				100	Inflammation,	
ore, expression of a gene-of-interest in				25			Virus & Bacteria	
, treatment with VB-201, PAF-like								and the second of the second
ologs, oxidized phospholipids, endothelial			(A)			· .		
specificity, anti-angiogenic adenovirus		'	100	1.0		in the table of		
ors, and treatment of Isohemia,								
roselerosis, vascular disease, inflammatory	Market Barrier			and the second			a Markettining,	
ase, cancer glioblastoma, wound healing.		and the second		1				
tumor related conditions,								
usive sublicense to use the "Vatican	10,00 %	Net Sales	Sublicense, Trade	Worldwide	No	Consumer	Stationery	Minimum Royalty,
ervatory" trade name and logo to design,	, ,	,	Name	with	,,,,	Products	Diamentor;	Sublicense Royalty
ufacture, sell, distribute and advertise.			,	Exceptions		, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Capitod the Endylate
lous themed products for funerary use,								
iding urns, cremation keepsakes,								
te More	•							
eligian, caracing a company of the second	en en en en en en			13.4 (2	The second of the		to the control	4 1 1 1 1 1 1 1 1 1 1
usive patent, technology and know-how	8.00 %	Net Salés	Patent, Research,	Worldwide	Yes	Pharmaceutical	Gerietic,	Milestone Payment,
se to manufacture, market and sublicense	6.00 %		Technology			& Blotech	Vaccines	Other Payments
enteral injectable vaccine containing the							Constant and the	
xyettiylene/polyoxypropylene copolymer				-				
vant known as "CRL-1005"							and the state of	
oined Mare								Aug Tall Control
n to a co-exclusive patent, technology now-how license to develop, racture, use, distribute and sell an	10.00 % 6.00 %	Not Sales	Option, Patent, Research	-Unknown	Yés:	Pharmaceutical & Biotech	Assay test, Cold & Flu; Vaccines, Virus & Bacteria	Upfront Payment, Oth Payments
table vaccine containing the nonionid lymer known as "CBL-1005" combined fluvinna More:								

Upfront Payment, Minkruum, Royalty	Upíron: Payment				18play: 30 (\$
Option				8 g	Rows to display:
	Webcasting		al Cancer, Genetic, Vaccines, Unitary & Uncludy Wasteria	al Cancer, Genetto, Vaccines, Urinary & Urology, Virus & Bacriera	10,000
Consumer Products	Consumer Products Consumer Products,	Proad casting.	Pharmaceutoal & Biopech Bharmaceutoal & Biotech	Pharmaceutical & Elotech A Elotech Pharmaceutical & Biotech	2007
States Canada, Ye United States	Vinited Ye. States. States. Australia, Ye. Carrada,	Birope, Japan, New Japan, New Can Word United No	Unjerown Yes	Worldwide No	6.819
			Ainendment, Pateirr U. Asset Purhäse, W. Patenir	The same	3.000
Copyrights, Trademark	Copyrights, Tradenark Copyrights.	Amendruen. Copytights, Trademerk	Anend Asset P Patent	Parent Cross-Loense (Know-how, Pa Technology	2.090
Net Sales	Net Sales	Net Sales	Net Sales	Net Sales	1.000
10.00 %	8.00.%	12.00 %	5,46 % 5,96 % 2,172 %	2.66 %	### ### ### ### ### ### ### ### ### ##
distribute, so of branded to formeral opplygms to opplygms to one and sell a ums. through be;	e Coussara State and indicida to bute and self. Iskels: Lins. and e to use the "Star promote,	uns. arai homes. crai homes. de, Major League. aal chubs' agos 10 oie, advertise.and	nent for patiented naturity date of natu	a Purchase To neguding less interchase To neguding less interchous autologous gyr cross-license er, offer, and sell make, et, offer, and sell mustiches,	(122) Per (59)
designs to manufacture, distribute, note and sell a fundrary line of branded. It though mass retailers and funeral III. Note; exclusive license to use the The American nel Club ' trademarks and copyrights to uitacture, distribute, promote and sell a stray line of ACD branded urns, through pet, exhaus, mass retailers and rin More e chaus, mass retailers and rin More	exclusive fleanae to use the Louisiana State tersity name, trademarks, and indicida to utactiure, advertise, distribute and self norial products such as caskets, turs. and is: exclusive copyright literase to use the "Star exclusive copyright literase to use the "Star".	ulfacture and sell caskets, urns, numents and vaults to funeral homes. Indirent to nonexolusive liberes to use the arican and National Leagues, Major Leagues eball, and Individual baseball othos emarks, copyrights, and legos to utfacture, distribute, promote, advertise and title.	andment to royally agreement for patented of hissory note. Inissory note. Thase of rights related with patentied harmaceutical products, knotuding infarmaceutical products, knotuding colonal antibodies, peptides, infectious ese and cancer vaccines, autologous per vaccines such as for non-Hodgieins onema an More	sement pursuant to a None Purchase to ide a royally for patented harmaceutical products, including holonal antibodies, pentides, intercious age and cancer vaccines, autologous ser vaccines and technology cross-license usive patent and technology cross-license royalty, fee krow-holy, iterate to make a made, use, import, marker, offer, and sell vGDF-8, TGF-B, Ferrior formulations.	victores, receptures, autopause insperimental control of the contr
designs' note and i, though it. Asore exclusive nel Club unfacture explans, exchans,	exclusive rersity of the control of	ulfacture iuments sindment andment any eball and ematrics, virtacture, kore	andmentro or ogic producit hissory nota, sharmaceuric inclorat and ese and card cer vaccines:	Perment ide ark inamer locional esse and carvaco carvaco lusiva professional esse and capture a made, capture	W W



ROTALITOTAL		DASHBOARD SEASON MY ACCOUNT FEATURES >
License Agreements Search		
	is 2 Keyword Search CTerritory	Datangible Muraban
Industry 🕙	policiping	Agreement Type ()
		Related Parties (
		化物理学 机加强电子电子 化二氯化物 医电子 人名英格兰人姓氏克里克的变体 医克里克氏病 医多种性病 医多种性病 医甲基苯酚 医二甲基甲基酚 医多种性病 医多种生物 医皮肤皮肤皮肤皮肤皮肤皮肤皮肤皮肤皮肤皮肤皮肤皮肤皮肤皮肤皮肤皮肤皮肤皮肤皮肤
Company Name	Licensee or Elcensor - v	Reference.Num. (*)
OIX		
Licensor Type	fr.	Licensee Type
		NAICS Code 🚯
Royalty Fate Pange	; · · · · · · · · · · · · · · · · · · ·	Exclusivity ©
Tiered Royalty. 🚯		Additional Payments. (*)
		Famous Brand 💸
Snow Flags		

Licensed Territory	Licepson's Territory
in children in the control of the co	
	Licensee's Territory
SEC Fled Date 🐧 From	Effective Date (1)
Duration (Activate Date (
TAPOECICA TILE TO THE	
Intangible Number Country:	Intangible Number:
Intangible Number Type: 🐠	Application Number:
Description of Intangibles (*) Advanced (*)	Full Text Search Oulcik Advanced

Contact | Privacy Policy | Log off



Reference:

L13775

0001289370

CIK: IRS:

00000000

SEC Filer Name:

MetaMorphix Inc.

Agreement Title:

Cross-License Agreement

Effective Date:

10/14/2002

Agreement Type:

Cross-License; Know-how; Patent; Technology

Industry:

Pharmaceutical & Biotech

SIC Code:

2834

NAICS Code:

325412

Licenson

MetaMorphix, Inc.

Licensor's Country:

United States

Licensee:

Wyeth f/k/a American Home Products Corp. through Genetics Institute, L.L.C. f/k/a Genetics

Date: 11/20/2015

Institute, Inc.

Licensee's Country:

United States

Royalty Rate:

2,00%

Royalty Base:

Net Sales

Original Base:

Net Sales

Tiered Royalty:

No

Duration (Year):

20.0

Licensed Territory:

Unknown Exclusive

Exclusivity:

Description of Intangibles: Exclusive patent and technology cross-license with royalty-free know-how license to make, have made, use, import, market, offer, and sell the "GDF-8" TGF-B Factor formulations, antibodies, receptors, anitsense molecules, pharmaceutical products, antagonists, vaccines and modulators.

Comments:

Expansion of exclusive patent and technology cross-license. Secs. 2.1 and 2.2. Nonexclusive royalty-free know-how license. Secs. 2.1 and 2.2. Royalty to each party is 2% of net sales. Secs. 4.1 and 4.2. Royalty is incremental to royalties payable under the 1999 Agreement. Secs. 4.1 and 4.2. Related to AutoID 10600, et al.



Reference:

L14928

GVKEY:

150200

CIK;

0000704384

IRS:

411412084

SEC Filer Name:

BIOVEST INTERNATIONAL INC

Agreement Title:

Royalty Agreement

Effective Date:

12/10/2007

Agreement Type:

Patent

Industry:

Pharmaceutical & Biotech

SIC Code:

2834

NAICS Code:

325412

Licensor:

Valens U.S. SPV I, LLC

Licensor's Country:

United States

Licensee:

Biovest International, Inc.

Licensee's Country:

United States

Royalty Rate;

2.88 %

Royalty Base:

Net Sales

Original Base:

Net Sales

Tiered Royalty:

No

Duration (Year):

Perpetual

Licensed Territory:

Worldwide

Exclusivity:

Unknown

Description

of Intangibles:

Agreement pursuant to a Note Purchase to provide a royalty for patented biopharmaceutical products, including monoclonal antibodies, peptides, infectious disease and cancer vaccines, autologous cancer vaccines such as for non-Hodgkins lymphoma and renal cell cardinoma, cell-based therapies, stem cells, cytokines, and viruses produced by mammalian cell culture

techniques.

Comments:

Royalty agreement for patented products. Art. 4.1. Royalty is 2.88% of net sales. Art. 4.1. Term is as long as Biovest commercializes products. Art. 7.1. Related to AutoIDs 14929, 15020.



Reference:

L14929

GVKEY:

150200

CIK:

0000704384

IRS:

411412084

SEC Filer Name:

BIOVEST INTERNATIONAL INC

Agreement Title:

Royalty Agreement

Effective Date:

12/10/2007

Agreement Type:

Asset Purchase; Patent

Industry:

Pharmaceutical & Blotech

SIC Code:

2834

NAICS Code:

325412

Licensor:

Valens Offshore SPV II Corp.

Licensor's Country:

United States

Licensee:

Biovest International, Inc.

Licensee's Country:

United States

Royalty Rate:

2.12 %

Royalty Base:

Net Sales

Original Base:

Net Sales

Tiered Royalty:

No

Duration (Year):

Perpetual

Licensed Territory:

Worldwide

Exclusivity:

Unknown

Description

of Intangibles:

Purchase of rights related with patented biopharmaceutical products, including monoclonal antibodies, peptides, infectious disease and cancer vaccines, autologous cancer vaccines such as

for non-Hodgkins lymphoma and renal cell carcinoma, cell-based therapies, stem cells, cytokines, and viruses produced by mammalian cell culture techniques.

Comments:

Asset purchase, including patents, Recitals and Sec. 4.1. Royalty is 2,12% of net sales. Sec. 4.1. Term is as long as Biovest commercializes products. Sec. 7.1. Related to AutoIDs 14928

and 15020.



Reference:

L15020

GVKEY:

162956

CIK:

0001310094

IRS:

00000000

SEC Filer Name:

ACCENTIA BIOPHARMACEUTICALS INC

Agreement Title:

Royalty Agreement Amendment

Effective Date:

5/30/2008

Agreement Type:

Amendment; Patent

Industry:

Pharmaceutical & Biotech

SIC Code:

2834

NAICS Code:

325412

Licensor:

Valens Offshore SPV II, Corp.

Licensor's Country:

Unknown

Licensee:

Blovest International, Inc.

Licensee's Country:

United States

Royalty Rate:

9.46 %

Royalty Base:

Net Sales

Original Base:

Net Sales

Tiered Royalty:

Yes

Duration (Year):

Unknown

Licensed Territory:

Unknown

Exclusivity:

Unknown

Description

of Intangibles:

Amendment to royalty agreement for patented biologic products to extend maturity date of

promissory note.

Comments:

Letter amendment for license to sell patented products. Royalty is 9,46% of net sales. Royalty will be reduced to 5,96% or 6,96% if licensee pays at least \$10,000,000 to LV Administrative Services, Inc. for its administrative and collateral agent services. Related to AutoID 14929.



Reference:

L16228

GVKEY:

24887

CIK:

0001029802

IRS:

58-2027283

SEC Filer Name:

VAXCEL INC.

Agreement Title:

Option Agreement

Effective Date:

10/13/1995

Agreement Type:

Option; Patent; Research

Industry:

Pharmaceutical & Blotech

SIC Code:

2836

NAICS Code;

325414

Licensor:

Vaxcel, Inc.

Licensor's Country:

United States

Licensee:

Medeva Europe Ltd.

Licensee's Country:

United Kingdom

Royalty Rate:

10.00 %

Royalty Base:

Net Sales

Royalty Opac.

.

Original Base:

Net Sales

Tiered Royalty:

Yes

Additional Payments:

Upfront Payment; Other Payments

Duration (Year):

2.0

Licensed Territory:

Uhknown

Exclusivity:

Non-Exclusive

Description

of Intangibles:

Option to a co-exclusive patent, technology and know-how license to develop, manufacture, use, distribute and sell an injectable vaccine containing the nonionic copolymer known as "CRL-1005" combined with fluvirina, a purified-surface-antigen influenza virus vaccine, to enhance the

Immune response in humans through Phase I human clinical trials.

Other Payments:

Payment is \$90,000 upon signing. Sec. 4.1. Payment is \$250,000 if an IND or CTX for the product has not been submitted to any 1 regulatory agency within 1 year from the effective date; \$160,000 if an IND or CTX for the product is submitted to any 1 regulatory agency; and \$250,000 upon completion of the Phase I human clinical trials. Secs. 4.2, 4.3 and 4.4. If option is exercised, payment is \$250,000 upon completion of the Phase II human clinical trials; \$300,000 upon completion of the Phase III human clinical trials; \$50,000 per month if Phase II does not comence within 6 months after completion of Phase II; \$300,000 upon each submission of a Product License Application or New Drug Application to the FDA or the MCA; \$1,500,000 upon approval for product commercialization in the United States; \$1,150,000 upon approval for product commercialization per country other than USA or UK, until \$1,200,000 has been paid. Secs. 6.2.4 through 6.2.9.

Intangible Number:

Patent Appl. No. 08/292,814 "Nonionic Block Copolymers," Appx. 1.

Case 8:15-cv-03940-GJH Document 1 Filed 12/23/15 Page 57 of 66

Comments:

Co-exclusive patent, technology and know-how license. Secs. 2.1 and 7.1. Parties shall jointly develop the program for the Phase I clinical trials. Sec. 3.1. Option to license. Sec. 5.1. If option is exercised, payment is \$300,000 for the supply agreement. Sec. 6.2.1. Royalty is between 6% and 10% of net sales, depending on the efficacy profile and production benefits of the product. Sec. 6.2.13.



Reference:

L16244

GVKEY:

24887

CIK:

0001029802

IRS:

58-2027283

SEC Filer Name:

VAXCEL INC

Agreement Title:

Feasibility Evaluation/Development Option Agreement

Effective Date:

8/4/1995

Agreement Type:

Patent; Research; Technology

Industry:

Pharmaceutical & Blotech

SIC Code:

2836

NAICS Code:

325414

Licensor:

Vaxcel, Inc.

Licensor's Country:

United States

Licensee:

Connaught Laboratories, Inc.

Licensee's Country:

United States

Royalty Rate:

8.00 %

Royalty Base:

Net Sales

Original Base:

Net Sales

Tiered Royalty:

Yes

Additional Payments:

Milestone Payment; Other Payments

Duration (Year):

15.0

Licensed Territory:

Worldwide

Exclusivity:

Exclusive

Description

of Intangibles:

Exclusive patent, technology and know-how-license to manufacture, market and sublicense a parenteral injectable vaccine containing the polyoxyethylene/polyoxypropylene copolymer adjuvant known as "CRL-1005" combined with recombinant lipidated outer surface protein A "OspA" from Borrella burgdorferi, the causative agent of lyme disease.

Other Payments:

Payment to evaluate the product is \$25,000 upon signing. Sec. 2.2. If preclinical evaluation is successful, payment is \$20,000 for exclusive development rights through Phase I clinical trials. Sec. 2.2. Milestone payments are \$250,000 upon beginning of Phase II; \$250,000 upon beginning of Phase III; \$500,000 upon PLA filling; \$1,000,000 upon FDA/CBER approval; \$100,000 per country regulatory approval up to \$500,000. Sec. 4.

Comments:

Exclusive patent, technology and know-how license. Recitals and Sec. 4. Parties shall jointly develop the program. Sec. 2.1. After the program, parties shall negotiate a license agreement. Sec. 4. License issue fee is \$500,000. Sec. 4. Royalty will be between 6% and 8% of net sales. Sec. 4. Duration of the agreement is 2 years, but future license is for the life of patents. Secs. 4 and 6.1.



Reference:

L28470

GVKEY:

21209

CIK:

0001603207

IRS:

000000000

SEC Filer Name:

Vascular Biogenics Ltd.

Agreement Title:

Agreement

Effective Date:

02/03/2013

Agreement Type:

Copyrights; Know-how; Patent; Process; Trade Name; Trademark

Industry:

Pharmaceutical & Biotech

SIC Code:

2834

NAICS Code:

325412

Licensor:

Tel Hashomer - Medical Research, Infrastructure and Services Ltd.

Licensor's Country:

Israel

Licensee:

Vascular Biogenics Ltd.; Dror Harats

Licensee's Country:

Royalty Rate:

1.00 %

Royalty Base:

Net Sales

Original Base:

Net Sales

Tiered Royalty:

No

Additional Payments:

Sublicense Royalty

Duration (Year):

20.0

Licensed Territory:

Worldwide

Exclusivity:

Unknown

Description

of Intangibles:

Settlement of dispute, with patent, know-how, process, copyrights, trade names and trademark license to develop, manufacture, sell, market and sublicense products and devices related to enhancing targeting of viral vectors, expression of a gene-of-interest in cells, treatment with VB-201, PAF-like homologs, oxidized phospholipids, endothelial cell specificity, anti-angiogenic adenovirus vectors, and treatment of ischemia, atherosclerosis, vascular disease, inflammatory disease, cancer, glioblastoma, wound healing, and tumor related conditions.

Intangible Number:

Patent and Appl. Nos. PCT WO2011/083469 "Treatment with VB-201;" WO2009/050692 "PAF-Like Homologs And Uses Thereof;" WO2006/006161, IL 180628, JP 4,767,948, KR 10-1201935, CN 200580029218.9, RU 2399626, MX 284830, 303011, AU 2007200090, "Improved Process For The Preparation Of Oxidized Phospholipids;" US 7,067,649, 7,579,327, PCT IL03/00347, SG 200406381-4, ZA 2004/8989, JP 2004-501545, CA 2,483,996, MX PA/a/2004/010711. "Promoters Exhibiting Endothelial Cell Specificity And Methods Of Using NOT MICE WO 2004/016715." PCT WO 2004/015675. Same;" PCT WO2011/083467 "Combined Treatment Utilizing VB-201;" PCT WO/2008/015675,

CN Z120078003 5863.0, AU 2007280017, NZ 574410, ZA 2009/00581, SG 149616(WO2008/015675) "Polypeptides And Polynucleotides Encoding Same And Use Thereof In The Treatment Of Medical Conditions Associated With Ischemia." See Appx. B for complete list.

Case 8:15-cv-03940-GJH Document 1 Filed 12/23/15 Page 60 of 66

Comments:

Settlement of dispute. Recitals. Patent, know-how, process, copyrights, trade names and trademark license. Sec. 1.3.8. Right to sublicense. Sec. 3.1. Royalty is 1% of net sales. Sec. 4.1.1. Sublicense consideration is 2% of license fees. Sec. 4.1.2. Net sales include sales by sublicensees. Sec. 1.3.9. Sublicense fees include lump sums, license fees and milestone payments. Sec. 1.3.9. Term is the later of life of the patents or 15 years from 1st commercial sale in each country. Sec. 4.1.

http://www.royaltystat.com
Copyright © 2015 RoyaltyStat® All Rights Reserved
Distribution of this document is restricted under RoyaltyStat's Terms of Use.

الإعلاقان



Reference:

L28471

GVKEY:

21209

CIK:

0001603207

IRS:

00000000

SEC Filer Name:

Vascular Biogenics Ltd.

Agreement Title:

Commercial Gene Therapy License Agreement

Effective Date:

4/15/2011

Agreement Type:

Know-how; Patent; Process

Industry:

Pharmaceutical & Biotech

SIC Code:

2834

NAICS Code:

325412

Licensor:

Crucell Holland BV

Licensor's Country:

Netherlands, Netherlands

Licensee:

Vascular Biogenics Ltd.

Licensee's Country:

Israel, Israel

Royalty Rate:

2.00 %

Royalty Base:

Net Sales

Original Base:

Net Sales

Tiered Royalty:

No

Additional Payments:

License Fee; Milestone Payment.

Duration (Year):

20.0

Licensed Territory:

Worldwide

Exclusivity:

Non-Exclusive

Description

of Intangibles:

Nonexclusive patent, know-how and process license to develop, use, import, manufacture, have made, offer and sell pharmaceutical products consisting of DNA sequences obtained from the Per:C6 cells using licensee's vascular targeting system platform in combination with the genome of a serotype 5 human adenovirus, to treat cancer in humans using an adenoviral vector,

including therapeutic gene sequences, but not serving as a vaccine.

Other Payments:

Licensee fee is 75,000 Euros. Sec. 4.1.1. License maintenance fee is 100,000 Euros annually. Sec. 4.1.2. Milestone payments are non-creditable and are 400,000 Euros upon approval of 1st


indication for each product. Sec. 4.2.

Comments:

Nonexclusive patent, know-how and process license. Sec. 2.1. Royalty is 1.5% of net sales for products covered by know-how, 0.5% of net sales for products covered by a patent, and a total of 2% of net sales for products covered by both. Sec. 4.3. Royalty for products covered only by know-how will be due for 10 years from 1st commercial sale. Sec. 4.3.1.


MY ACCOUNT . FEATURES >

DASHBOARD SEARCH



DASHBOARD SEARCH MY ACCOUNT ~ FEATURES ~







DATABASE | ADMIN | CONTACT | LOG OFF

DASHBOARD | SEARCH | MYACCOUNT & | FEATURES &

Contractual Terms

UNFILTERED ROYALTY RATES

15

17.5

26

25

25

25

Display Download as T

Contact | Privacy Policy | Log off

FEATURES ~

DASHBOARD | SEARCH | MY ACCOUNT >



111 Download as Display Net Sales % All Agreements UNFILTERED ROYALTY RATES Contractual Terms & Territory - Region 17.5 52 9 7.5 **SnotteviesdO**

DASHBOARD | SEARCH | MY ACCOUNT > | FEATURES >



Download as Tienta Display Net Sales % All Agreements UNFILTERED ROYALTY RATES Contractual Terms 6 Trered Royalty Rate 12 Οβεσιλέήσυτε